KR20190108118A - 신경계 장애의 치료를 위한 방법 - Google Patents
신경계 장애의 치료를 위한 방법 Download PDFInfo
- Publication number
- KR20190108118A KR20190108118A KR1020197022664A KR20197022664A KR20190108118A KR 20190108118 A KR20190108118 A KR 20190108118A KR 1020197022664 A KR1020197022664 A KR 1020197022664A KR 20197022664 A KR20197022664 A KR 20197022664A KR 20190108118 A KR20190108118 A KR 20190108118A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- heteroaryl
- formula
- cycloalkyl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 281
- 208000012902 Nervous system disease Diseases 0.000 title claims abstract description 36
- 238000011282 treatment Methods 0.000 title claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 415
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 claims description 272
- 239000003112 inhibitor Substances 0.000 claims description 263
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 201000010099 disease Diseases 0.000 claims description 25
- 230000001988 toxicity Effects 0.000 claims description 16
- 231100000419 toxicity Toxicity 0.000 claims description 16
- 108010060159 Apolipoprotein E4 Proteins 0.000 claims description 15
- 208000024827 Alzheimer disease Diseases 0.000 claims description 13
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 13
- 101100041816 Homo sapiens SCD gene Proteins 0.000 claims description 11
- 101000639987 Homo sapiens Stearoyl-CoA desaturase 5 Proteins 0.000 claims description 11
- 101150097713 SCD1 gene Proteins 0.000 claims description 11
- 102100033930 Stearoyl-CoA desaturase 5 Human genes 0.000 claims description 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 9
- 210000002569 neuron Anatomy 0.000 claims description 9
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 230000002776 aggregation Effects 0.000 claims description 8
- 238000004220 aggregation Methods 0.000 claims description 8
- 230000007850 degeneration Effects 0.000 claims description 8
- 206010012289 Dementia Diseases 0.000 claims description 7
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 7
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 6
- 201000010374 Down Syndrome Diseases 0.000 claims description 5
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 5
- 201000002832 Lewy body dementia Diseases 0.000 claims description 5
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 208000011403 Alexander disease Diseases 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 241000238557 Decapoda Species 0.000 claims description 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 3
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000027747 Kennedy disease Diseases 0.000 claims description 3
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 3
- 208000024777 Prion disease Diseases 0.000 claims description 3
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 3
- 201000004810 Vascular dementia Diseases 0.000 claims description 3
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims description 3
- 229960003920 cocaine Drugs 0.000 claims description 3
- 230000001054 cortical effect Effects 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 201000010901 lateral sclerosis Diseases 0.000 claims description 3
- 208000005264 motor neuron disease Diseases 0.000 claims description 3
- 210000000278 spinal cord Anatomy 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 108700028369 Alleles Proteins 0.000 claims description 2
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 claims description 2
- 206010049020 Encephalitis periaxialis diffusa Diseases 0.000 claims description 2
- 208000015872 Gaucher disease Diseases 0.000 claims description 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 2
- 102100024127 Pantothenate kinase 2, mitochondrial Human genes 0.000 claims description 2
- 208000021235 Schilder disease Diseases 0.000 claims description 2
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 206010044688 Trisomy 21 Diseases 0.000 claims description 2
- 238000009825 accumulation Methods 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 230000001028 anti-proliverative effect Effects 0.000 claims description 2
- 230000000561 anti-psychotic effect Effects 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 239000002249 anxiolytic agent Substances 0.000 claims description 2
- 230000000949 anxiolytic effect Effects 0.000 claims description 2
- 239000002475 cognitive enhancer Substances 0.000 claims description 2
- 229960003638 dopamine Drugs 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 210000004498 neuroglial cell Anatomy 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 claims description 2
- 230000002360 prefrontal effect Effects 0.000 claims description 2
- 239000000932 sedative agent Substances 0.000 claims description 2
- 230000001624 sedative effect Effects 0.000 claims description 2
- 150000003384 small molecules Chemical group 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 102000003802 alpha-Synuclein Human genes 0.000 claims 5
- 208000027061 mild cognitive impairment Diseases 0.000 claims 4
- 108010025628 Apolipoproteins E Proteins 0.000 claims 3
- 102000013918 Apolipoproteins E Human genes 0.000 claims 3
- 208000037259 Amyloid Plaque Diseases 0.000 claims 1
- 206010008027 Cerebellar atrophy Diseases 0.000 claims 1
- 208000024412 Friedreich ataxia Diseases 0.000 claims 1
- 206010063491 Herpes zoster oticus Diseases 0.000 claims 1
- 240000007817 Olea europaea Species 0.000 claims 1
- 208000032831 Ramsay Hunt syndrome Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 102000019355 Synuclein Human genes 0.000 claims 1
- 108050006783 Synuclein Proteins 0.000 claims 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011349 geniculate herpes zoster Diseases 0.000 claims 1
- 230000004845 protein aggregation Effects 0.000 claims 1
- 239000004576 sand Substances 0.000 claims 1
- 208000037820 vascular cognitive impairment Diseases 0.000 claims 1
- 210000004885 white matter Anatomy 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 abstract description 5
- 125000000217 alkyl group Chemical group 0.000 description 613
- 239000001257 hydrogen Substances 0.000 description 331
- 229910052739 hydrogen Inorganic materials 0.000 description 331
- 125000001072 heteroaryl group Chemical group 0.000 description 323
- 108010087894 Fatty acid desaturases Proteins 0.000 description 254
- 125000000753 cycloalkyl group Chemical group 0.000 description 239
- 125000003118 aryl group Chemical group 0.000 description 228
- 125000000623 heterocyclic group Chemical group 0.000 description 218
- 235000019000 fluorine Nutrition 0.000 description 198
- 150000002431 hydrogen Chemical class 0.000 description 190
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 164
- 229910052736 halogen Inorganic materials 0.000 description 161
- 150000002367 halogens Chemical class 0.000 description 161
- 229910052731 fluorine Inorganic materials 0.000 description 150
- 239000011737 fluorine Substances 0.000 description 149
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 142
- 125000003710 aryl alkyl group Chemical group 0.000 description 138
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 130
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 130
- 125000001424 substituent group Chemical group 0.000 description 127
- 125000003545 alkoxy group Chemical group 0.000 description 117
- -1 —OR 1 Chemical group 0.000 description 109
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 100
- 125000001153 fluoro group Chemical group F* 0.000 description 89
- 150000003839 salts Chemical class 0.000 description 86
- 125000004093 cyano group Chemical group *C#N 0.000 description 84
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 80
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 79
- 229910052799 carbon Inorganic materials 0.000 description 74
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 73
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 71
- 125000003342 alkenyl group Chemical group 0.000 description 64
- 229910052760 oxygen Inorganic materials 0.000 description 59
- 229910052717 sulfur Inorganic materials 0.000 description 56
- 150000001721 carbon Chemical group 0.000 description 55
- 125000005020 hydroxyalkenyl group Chemical group 0.000 description 52
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 46
- 125000001624 naphthyl group Chemical group 0.000 description 44
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 40
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 description 36
- 125000001188 haloalkyl group Chemical group 0.000 description 36
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 35
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 35
- 125000004414 alkyl thio group Chemical group 0.000 description 34
- 125000000304 alkynyl group Chemical group 0.000 description 33
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 33
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 30
- 125000005843 halogen group Chemical group 0.000 description 29
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 28
- 125000004043 oxo group Chemical group O=* 0.000 description 28
- 239000000651 prodrug Substances 0.000 description 28
- 229940002612 prodrug Drugs 0.000 description 28
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 24
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 23
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 23
- 125000005842 heteroatom Chemical group 0.000 description 23
- 229920000728 polyester Polymers 0.000 description 23
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 22
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 21
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 20
- 125000001309 chloro group Chemical group Cl* 0.000 description 20
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 description 19
- 125000002950 monocyclic group Chemical group 0.000 description 19
- 125000002947 alkylene group Chemical group 0.000 description 17
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 15
- 125000004450 alkenylene group Chemical group 0.000 description 15
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 15
- 125000004429 atom Chemical group 0.000 description 15
- 125000003282 alkyl amino group Chemical group 0.000 description 14
- 125000004122 cyclic group Chemical group 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 125000004076 pyridyl group Chemical group 0.000 description 14
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 13
- 125000001544 thienyl group Chemical group 0.000 description 13
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 12
- 125000004419 alkynylene group Chemical group 0.000 description 11
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 11
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 10
- QBPUOAJBMXXBNU-UHFFFAOYSA-N 3-phenyl-1H-pyrazole-5-carboxylic acid Chemical compound N1C(C(=O)O)=CC(C=2C=CC=CC=2)=N1 QBPUOAJBMXXBNU-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 10
- 125000001769 aryl amino group Chemical group 0.000 description 10
- 125000002883 imidazolyl group Chemical group 0.000 description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 102100026882 Alpha-synuclein Human genes 0.000 description 8
- 125000002252 acyl group Chemical group 0.000 description 8
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 8
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 8
- 125000003435 aroyl group Chemical group 0.000 description 8
- 125000005110 aryl thio group Chemical group 0.000 description 8
- 125000000000 cycloalkoxy group Chemical group 0.000 description 8
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 description 8
- 125000004663 dialkyl amino group Chemical group 0.000 description 8
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 8
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 description 8
- 125000003368 amide group Chemical group 0.000 description 7
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 7
- 125000004104 aryloxy group Chemical group 0.000 description 7
- 125000004986 diarylamino group Chemical group 0.000 description 7
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 description 7
- 125000001786 isothiazolyl group Chemical group 0.000 description 7
- 125000000842 isoxazolyl group Chemical group 0.000 description 7
- 125000002971 oxazolyl group Chemical group 0.000 description 7
- 125000003226 pyrazolyl group Chemical group 0.000 description 7
- 239000012453 solvate Substances 0.000 description 7
- 125000000335 thiazolyl group Chemical group 0.000 description 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 7
- 125000006694 (C2-C10) heterocyclyl group Chemical group 0.000 description 6
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 6
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 6
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 6
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 125000005553 heteroaryloxy group Chemical group 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 125000004385 trihaloalkyl group Chemical group 0.000 description 6
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 5
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 5
- CFLQPPVBAQNLTQ-UHFFFAOYSA-N 1-pyridin-3-yltriazole-4-carboxylic acid Chemical compound N1=NC(C(=O)O)=CN1C1=CC=CN=C1 CFLQPPVBAQNLTQ-UHFFFAOYSA-N 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 125000004438 haloalkoxy group Chemical group 0.000 description 5
- 210000002241 neurite Anatomy 0.000 description 5
- 229910052720 vanadium Inorganic materials 0.000 description 5
- 125000006715 (C1-C5) alkylthio group Chemical group 0.000 description 4
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 4
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 4
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 4
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 4
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 4
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 4
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 4
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 4
- 125000005129 aryl carbonyl group Chemical group 0.000 description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 4
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 4
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 4
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000003373 pyrazinyl group Chemical group 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 description 3
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 3
- GFQYKYPGSBTSII-HHHXNRCGSA-N 4-[[(2r)-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazol-2-yl]methoxy]-n-[2-oxo-2-[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]ethyl]benzamide Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1C(=O)NCC(=O)N(CC1)CCC1OC1=CC=C(OC(F)(F)F)C=C1 GFQYKYPGSBTSII-HHHXNRCGSA-N 0.000 description 3
- VZTKTOKASVGDFZ-UHFFFAOYSA-N 4-amino-n-[2-[4-[[4-amino-5-(2,6-difluorobenzoyl)-1,3-thiazol-2-yl]amino]piperidin-1-yl]-2-oxoethyl]benzamide Chemical compound S1C(C(=O)C=2C(=CC=CC=2F)F)=C(N)N=C1NC(CC1)CCN1C(=O)CNC(=O)C1=CC=C(N)C=C1 VZTKTOKASVGDFZ-UHFFFAOYSA-N 0.000 description 3
- 125000003830 C1- C4 alkylcarbonylamino group Chemical group 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 125000004949 alkyl amino carbonyl amino group Chemical group 0.000 description 3
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 3
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 3
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 3
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 3
- 125000005162 aryl oxy carbonyl amino group Chemical group 0.000 description 3
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- YBZAZJVFYNOKDB-UHFFFAOYSA-N n-[2-[4-(2,5-difluorophenoxy)piperidin-1-yl]-2-oxoethyl]-1-phenylimidazole-4-carboxamide Chemical compound FC1=CC=C(F)C(OC2CCN(CC2)C(=O)CNC(=O)C=2N=CN(C=2)C=2C=CC=CC=2)=C1 YBZAZJVFYNOKDB-UHFFFAOYSA-N 0.000 description 3
- KERBTFURRLPANO-UHFFFAOYSA-N n-[2-[4-[[4-amino-5-(2,6-difluorobenzoyl)-1,3-thiazol-2-yl]amino]piperidin-1-yl]-2-oxoethyl]-3-methylbenzamide Chemical compound CC1=CC=CC(C(=O)NCC(=O)N2CCC(CC2)NC=2SC(=C(N)N=2)C(=O)C=2C(=CC=CC=2F)F)=C1 KERBTFURRLPANO-UHFFFAOYSA-N 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 2
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 description 2
- 125000004515 1,2,4-thiadiazol-3-yl group Chemical group S1N=C(N=C1)* 0.000 description 2
- VLZSMKGNKCKWGB-UHFFFAOYSA-N 1-(2-cyanophenyl)-n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]triazole-4-carboxamide Chemical compound FC(F)(F)C1=CC=CC(OC2CCN(CC2)C(=O)CNC(=O)C=2N=NN(C=2)C=2C(=CC=CC=2)C#N)=C1 VLZSMKGNKCKWGB-UHFFFAOYSA-N 0.000 description 2
- YHIYGGJYAPGPEJ-UHFFFAOYSA-N 1-morpholin-4-yl-n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]triazole-4-carboxamide Chemical compound FC(F)(F)C1=CC=CC(OC2CCN(CC2)C(=O)CNC(=O)C=2N=NN(C=2)N2CCOCC2)=C1 YHIYGGJYAPGPEJ-UHFFFAOYSA-N 0.000 description 2
- AAJYKZWEWUTPKH-UHFFFAOYSA-N 5-anilino-n-[2-[4-(2-chloroanilino)piperidin-1-yl]-2-oxoethyl]pyridine-2-carboxamide Chemical compound ClC1=CC=CC=C1NC1CCN(C(=O)CNC(=O)C=2N=CC(NC=3C=CC=CC=3)=CC=2)CC1 AAJYKZWEWUTPKH-UHFFFAOYSA-N 0.000 description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 102100029470 Apolipoprotein E Human genes 0.000 description 2
- 101710095339 Apolipoprotein E Proteins 0.000 description 2
- 208000022526 Canavan disease Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 2
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- BWFZXKALYDFNKM-UHFFFAOYSA-N n-[2-[4-(2-chloroanilino)piperidin-1-yl]-2-oxoethyl]-5-phenyl-1,2-oxazole-3-carboxamide Chemical compound ClC1=CC=CC=C1NC1CCN(C(=O)CNC(=O)C2=NOC(=C2)C=2C=CC=CC=2)CC1 BWFZXKALYDFNKM-UHFFFAOYSA-N 0.000 description 2
- KSNATNDDQSJPIW-UHFFFAOYSA-N n-[2-[4-(2-chlorophenoxy)piperidin-1-yl]-2-oxoethyl]-1-phenylimidazole-4-carboxamide Chemical compound ClC1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C=2N=CN(C=2)C=2C=CC=CC=2)CC1 KSNATNDDQSJPIW-UHFFFAOYSA-N 0.000 description 2
- QRXORACKJIXAMU-UHFFFAOYSA-N n-[2-[4-(2-chlorophenoxy)piperidin-1-yl]-2-oxoethyl]-1-phenyltriazole-4-carboxamide Chemical class ClC1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C=2N=NN(C=2)C=2C=CC=CC=2)CC1 QRXORACKJIXAMU-UHFFFAOYSA-N 0.000 description 2
- OCZMEMHUQZONON-UHFFFAOYSA-N n-[2-[4-(5-chloropyridin-3-yl)oxypiperidin-1-yl]-2-oxoethyl]-1-cyclopentyltriazole-4-carboxamide Chemical compound ClC1=CN=CC(OC2CCN(CC2)C(=O)CNC(=O)C=2N=NN(C=2)C2CCCC2)=C1 OCZMEMHUQZONON-UHFFFAOYSA-N 0.000 description 2
- PEUIQJVBBWBMSQ-UHFFFAOYSA-N n-[2-[4-(5-cyano-2-methylphenoxy)piperidin-1-yl]-2-oxoethyl]-1-pyridin-3-yltriazole-4-carboxamide Chemical compound CC1=CC=C(C#N)C=C1OC1CCN(C(=O)CNC(=O)C=2N=NN(C=2)C=2C=NC=CC=2)CC1 PEUIQJVBBWBMSQ-UHFFFAOYSA-N 0.000 description 2
- KEKOLPIGAGGFCH-UHFFFAOYSA-N n-[2-[4-[n-methyl-2-(trifluoromethyl)anilino]piperidin-1-yl]-2-oxoethyl]-4-phenylbenzamide Chemical compound C=1C=CC=C(C(F)(F)F)C=1N(C)C(CC1)CCN1C(=O)CNC(=O)C(C=C1)=CC=C1C1=CC=CC=C1 KEKOLPIGAGGFCH-UHFFFAOYSA-N 0.000 description 2
- DSLPYHOJHSHWOO-UHFFFAOYSA-N n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound FC(F)(F)C1=CC=CC(OC2CCN(CC2)C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)=C1 DSLPYHOJHSHWOO-UHFFFAOYSA-N 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- OFEDIYWVFSSUSE-GFCCVEGCSA-N (2r)-3-[3-[5-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,3,4-thiadiazol-2-yl]-1,2,4-oxadiazol-5-yl]-2-hydroxypropanoic acid Chemical compound O1C(C[C@@H](O)C(O)=O)=NC(C=2SC(=NN=2)N2CCC(CC2)OC=2C(=CC=C(F)C=2)Br)=N1 OFEDIYWVFSSUSE-GFCCVEGCSA-N 0.000 description 1
- TUEPSNCMZAPHBW-LBPRGKRZSA-N (2s)-2-amino-3-[3-[5-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,3,4-thiadiazol-2-yl]-1,2,4-oxadiazol-5-yl]propanoic acid Chemical compound O1C(C[C@H](N)C(O)=O)=NC(C=2SC(=NN=2)N2CCC(CC2)OC=2C(=CC=C(F)C=2)Br)=N1 TUEPSNCMZAPHBW-LBPRGKRZSA-N 0.000 description 1
- OFEDIYWVFSSUSE-LBPRGKRZSA-N (2s)-3-[3-[5-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,3,4-thiadiazol-2-yl]-1,2,4-oxadiazol-5-yl]-2-hydroxypropanoic acid Chemical compound O1C(C[C@H](O)C(O)=O)=NC(C=2SC(=NN=2)N2CCC(CC2)OC=2C(=CC=C(F)C=2)Br)=N1 OFEDIYWVFSSUSE-LBPRGKRZSA-N 0.000 description 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- SHNCCWIDELXRFV-UHFFFAOYSA-N 1-(1-methylpiperidin-4-yl)-n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]triazole-4-carboxamide Chemical compound C1CN(C)CCC1N1N=NC(C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(C=CC=2)C(F)(F)F)=C1 SHNCCWIDELXRFV-UHFFFAOYSA-N 0.000 description 1
- FNODJHAVPFMOBB-UHFFFAOYSA-N 1-(1-methylpyrrolidin-3-yl)-n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]triazole-4-carboxamide Chemical compound C1N(C)CCC1N1N=NC(C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(C=CC=2)C(F)(F)F)=C1 FNODJHAVPFMOBB-UHFFFAOYSA-N 0.000 description 1
- TYADALMGYXRAPP-UHFFFAOYSA-N 1-(2-methylphenyl)-n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]triazole-4-carboxamide Chemical compound CC1=CC=CC=C1N1N=NC(C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(C=CC=2)C(F)(F)F)=C1 TYADALMGYXRAPP-UHFFFAOYSA-N 0.000 description 1
- TYSGGYBJEXHAKO-UHFFFAOYSA-N 1-(3-fluorophenyl)-n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]triazole-4-carboxamide Chemical compound FC1=CC=CC(N2N=NC(=C2)C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(C=CC=2)C(F)(F)F)=C1 TYSGGYBJEXHAKO-UHFFFAOYSA-N 0.000 description 1
- YVDSFJVIPJIDDM-UHFFFAOYSA-N 1-(3-methylphenyl)-n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]triazole-4-carboxamide Chemical compound CC1=CC=CC(N2N=NC(=C2)C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(C=CC=2)C(F)(F)F)=C1 YVDSFJVIPJIDDM-UHFFFAOYSA-N 0.000 description 1
- FQYWDWKZXRCZIZ-UHFFFAOYSA-N 1-[4-(2-chlorophenoxy)piperidin-1-yl]-2-[(4-phenylphenyl)methylamino]ethanone Chemical compound ClC1=CC=CC=C1OC1CCN(C(=O)CNCC=2C=CC(=CC=2)C=2C=CC=CC=2)CC1 FQYWDWKZXRCZIZ-UHFFFAOYSA-N 0.000 description 1
- RXRYMZDQIVBQLZ-UHFFFAOYSA-N 1-[4-(2-chlorophenoxy)piperidine-1-carbonyl]-n-(4-phenylphenyl)cyclopropane-1-carboxamide Chemical compound ClC1=CC=CC=C1OC1CCN(C(=O)C2(CC2)C(=O)NC=2C=CC(=CC=2)C=2C=CC=CC=2)CC1 RXRYMZDQIVBQLZ-UHFFFAOYSA-N 0.000 description 1
- HBRVWQZNYJKJEF-UHFFFAOYSA-N 1-cyclopropyltriazole-4-carboxylic acid Chemical compound N1=NC(C(=O)O)=CN1C1CC1 HBRVWQZNYJKJEF-UHFFFAOYSA-N 0.000 description 1
- IQDCGUJYWBWOGH-UHFFFAOYSA-N 1-piperidin-4-yltriazole-4-carboxylic acid Chemical compound N1=NC(C(=O)O)=CN1C1CCNCC1 IQDCGUJYWBWOGH-UHFFFAOYSA-N 0.000 description 1
- APVORTSBDKXMKN-UHFFFAOYSA-N 1-pyrrolidin-3-yltriazole-4-carboxylic acid Chemical compound N1=NC(C(=O)O)=CN1C1CNCC1 APVORTSBDKXMKN-UHFFFAOYSA-N 0.000 description 1
- FUQVEOXNFSKAFB-UHFFFAOYSA-N 2-[1-[2-[(3-phenyl-1h-pyrazole-5-carbonyl)amino]acetyl]piperidin-4-yl]oxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 FUQVEOXNFSKAFB-UHFFFAOYSA-N 0.000 description 1
- YIEBSWREUUAXDW-UHFFFAOYSA-N 2-[2-[2-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]acetic acid Chemical compound OC(=O)CC1=CSC(C=2SC(=NC=2)N2CCC(CC2)OC=2C(=CC=CC=2)C(F)(F)F)=N1 YIEBSWREUUAXDW-UHFFFAOYSA-N 0.000 description 1
- JWLBYNOERXCWJZ-UHFFFAOYSA-N 2-[3-[3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2,4-oxadiazol-5-yl]pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=CC(C=2ON=C(N=2)N2CCC(CC2)OC=2C(=CC=C(F)C=2)Br)=C1 JWLBYNOERXCWJZ-UHFFFAOYSA-N 0.000 description 1
- AJEOAFVABCUXLD-UHFFFAOYSA-N 2-[4-(4-amino-1,2-oxazol-3-yl)phenoxy]-1-phenylethanone;hydrochloride Chemical compound Cl.NC1=CON=C1C(C=C1)=CC=C1OCC(=O)C1=CC=CC=C1 AJEOAFVABCUXLD-UHFFFAOYSA-N 0.000 description 1
- FLXIYYSJKRIVEY-UHFFFAOYSA-N 2-[4-[3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2,4-oxadiazol-5-yl]pyrazol-1-yl]acetic acid Chemical compound C1=NN(CC(=O)O)C=C1C1=NC(N2CCC(CC2)OC=2C(=CC=C(F)C=2)Br)=NO1 FLXIYYSJKRIVEY-UHFFFAOYSA-N 0.000 description 1
- QUPWNRFVCHQBNJ-UHFFFAOYSA-N 2-[5-[2-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,3-oxazol-4-yl]tetrazol-2-yl]acetic acid Chemical compound OC(=O)CN1N=NC(C=2N=C(OC=2)N2CCC(CC2)OC=2C(=CC=C(F)C=2)Br)=N1 QUPWNRFVCHQBNJ-UHFFFAOYSA-N 0.000 description 1
- IYWWRTZDEZRNQS-UHFFFAOYSA-N 2-[5-[3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2,4-oxadiazol-5-yl]pyrazol-1-yl]acetic acid Chemical compound OC(=O)CN1N=CC=C1C1=NC(N2CCC(CC2)OC=2C(=CC=C(F)C=2)Br)=NO1 IYWWRTZDEZRNQS-UHFFFAOYSA-N 0.000 description 1
- UJEAABFSXKCSGI-UHFFFAOYSA-N 2-[5-[3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2-oxazol-5-yl]tetrazol-2-yl]acetic acid Chemical compound OC(=O)CN1N=NC(C=2ON=C(C=2)N2CCC(CC2)OC=2C(=CC=C(F)C=2)Br)=N1 UJEAABFSXKCSGI-UHFFFAOYSA-N 0.000 description 1
- QHGRDLNGTTUCJI-UHFFFAOYSA-N 2-[5-[3-[4-(5-bromo-2-chlorophenoxy)piperidin-1-yl]-1,2-oxazol-5-yl]tetrazol-2-yl]acetic acid Chemical compound OC(=O)CN1N=NC(C=2ON=C(C=2)N2CCC(CC2)OC=2C(=CC=C(Br)C=2)Cl)=N1 QHGRDLNGTTUCJI-UHFFFAOYSA-N 0.000 description 1
- ZVLMBPHBJWSLRF-UHFFFAOYSA-N 2-[5-[3-[4-[2-chloro-5-[4-(trifluoromethoxy)phenyl]phenoxy]piperidin-1-yl]-1,2-oxazol-5-yl]tetrazol-2-yl]acetic acid Chemical compound OC(=O)CN1N=NC(C=2ON=C(C=2)N2CCC(CC2)OC=2C(=CC=C(C=2)C=2C=CC(OC(F)(F)F)=CC=2)Cl)=N1 ZVLMBPHBJWSLRF-UHFFFAOYSA-N 0.000 description 1
- NUMPXYMPQNMFDG-UHFFFAOYSA-N 2-[5-[5-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,3,4-thiadiazol-2-yl]tetrazol-1-yl]acetic acid Chemical compound OC(=O)CN1N=NN=C1C1=NN=C(N2CCC(CC2)OC=2C(=CC=C(F)C=2)Br)S1 NUMPXYMPQNMFDG-UHFFFAOYSA-N 0.000 description 1
- SVTBUTPWEOUGGT-UHFFFAOYSA-N 2-[5-[5-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,3,4-thiadiazol-2-yl]tetrazol-2-yl]acetic acid Chemical compound OC(=O)CN1N=NC(C=2SC(=NN=2)N2CCC(CC2)OC=2C(=CC=C(F)C=2)Br)=N1 SVTBUTPWEOUGGT-UHFFFAOYSA-N 0.000 description 1
- MEDUDQBUYOHPBU-UHFFFAOYSA-N 2-[5-[5-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]-1,3,4-thiadiazol-2-yl]tetrazol-2-yl]acetic acid Chemical compound OC(=O)CN1N=NC(C=2SC(=NN=2)N2CCC(CC2)OC=2C(=CC=CC=2)C(F)(F)F)=N1 MEDUDQBUYOHPBU-UHFFFAOYSA-N 0.000 description 1
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 1
- KQLBIEOWAOZVSQ-UHFFFAOYSA-N 3-(2-fluorophenyl)-n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-1h-pyrazole-5-carboxamide Chemical compound FC1=CC=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(C=CC=2)C(F)(F)F)=NN1 KQLBIEOWAOZVSQ-UHFFFAOYSA-N 0.000 description 1
- JUFXJOISCAUTHT-UHFFFAOYSA-N 3-(2-hydroxyphenyl)-N-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-1H-pyrazole-5-carboxamide Chemical compound OC1=CC=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(C=CC=2)C(F)(F)F)=NN1 JUFXJOISCAUTHT-UHFFFAOYSA-N 0.000 description 1
- PGUINIIGAPIJHW-UHFFFAOYSA-N 3-(3-fluorophenyl)-n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-1h-pyrazole-5-carboxamide Chemical compound FC1=CC=CC(C=2NN=C(C=2)C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(C=CC=2)C(F)(F)F)=C1 PGUINIIGAPIJHW-UHFFFAOYSA-N 0.000 description 1
- QTSLIDXVXJXBFW-UHFFFAOYSA-N 3-(3-hydroxyphenyl)-n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-1h-pyrazole-5-carboxamide Chemical compound OC1=CC=CC(C=2NN=C(C=2)C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(C=CC=2)C(F)(F)F)=C1 QTSLIDXVXJXBFW-UHFFFAOYSA-N 0.000 description 1
- KMPXYPIPCJWKHZ-UHFFFAOYSA-N 3-(4-fluorophenyl)-n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-1h-pyrazole-5-carboxamide Chemical compound C1=CC(F)=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(C=CC=2)C(F)(F)F)=NN1 KMPXYPIPCJWKHZ-UHFFFAOYSA-N 0.000 description 1
- HKGJIJWIRCGJGI-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-N-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-1H-pyrazole-5-carboxamide Chemical compound C1=CC(O)=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(C=CC=2)C(F)(F)F)=NN1 HKGJIJWIRCGJGI-UHFFFAOYSA-N 0.000 description 1
- CCNKCKZXPKCPHA-UHFFFAOYSA-N 3-(4-phenylmethoxyphenyl)-1,2-oxazol-4-amine Chemical compound NC1=CON=C1C(C=C1)=CC=C1OCC1=CC=CC=C1 CCNKCKZXPKCPHA-UHFFFAOYSA-N 0.000 description 1
- HWFISERVBASJJB-UHFFFAOYSA-N 3-[1-[2-[(3-phenyl-1h-pyrazole-5-carbonyl)amino]acetyl]piperidin-4-yl]oxybenzoic acid Chemical compound OC(=O)C1=CC=CC(OC2CCN(CC2)C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)=C1 HWFISERVBASJJB-UHFFFAOYSA-N 0.000 description 1
- SENIBRBPGXJDBL-UHFFFAOYSA-N 3-[3-[3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2,4-oxadiazol-5-yl]pyrazol-1-yl]propanoic acid Chemical compound OC(=O)CCN1C=CC(C=2ON=C(N=2)N2CCC(CC2)OC=2C(=CC=C(F)C=2)Br)=N1 SENIBRBPGXJDBL-UHFFFAOYSA-N 0.000 description 1
- UIZMPZFUAYICAG-UHFFFAOYSA-N 3-[3-[5-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,3,4-thiadiazol-2-yl]-1,2,4-oxadiazol-5-yl]propanoic acid Chemical compound O1C(CCC(=O)O)=NC(C=2SC(=NN=2)N2CCC(CC2)OC=2C(=CC=C(F)C=2)Br)=N1 UIZMPZFUAYICAG-UHFFFAOYSA-N 0.000 description 1
- AGXUHCYXNASCQU-UHFFFAOYSA-N 3-[3-chloro-4-[[2-(trifluoromethyl)phenyl]methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=C(Cl)C(OCC=3C(=CC=CC=3)C(F)(F)F)=CC=2)=N1 AGXUHCYXNASCQU-UHFFFAOYSA-N 0.000 description 1
- GSBWTFYESSFYAF-UHFFFAOYSA-N 3-[4-(1,3-dihydroisoindol-2-ylmethyl)phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(CN3CC4=CC=CC=C4C3)=CC=2)=N1 GSBWTFYESSFYAF-UHFFFAOYSA-N 0.000 description 1
- ZKJLZBZLIKSEER-UHFFFAOYSA-N 3-[4-(2,3-dihydroindol-1-ylmethyl)phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(CN3C4=CC=CC=C4CC3)=CC=2)=N1 ZKJLZBZLIKSEER-UHFFFAOYSA-N 0.000 description 1
- HOFZUBUICNNTOE-UHFFFAOYSA-N 3-[4-(2,3-dimethylanilino)piperidin-1-yl]-3-oxo-n-(4-phenylphenyl)propanamide Chemical compound CC1=CC=CC(NC2CCN(CC2)C(=O)CC(=O)NC=2C=CC(=CC=2)C=2C=CC=CC=2)=C1C HOFZUBUICNNTOE-UHFFFAOYSA-N 0.000 description 1
- XPXXYCCHDJLLLG-UHFFFAOYSA-N 3-[4-(2,4-dimethylanilino)piperidin-1-yl]-3-oxo-n-(4-phenylphenyl)propanamide Chemical compound CC1=CC(C)=CC=C1NC1CCN(C(=O)CC(=O)NC=2C=CC(=CC=2)C=2C=CC=CC=2)CC1 XPXXYCCHDJLLLG-UHFFFAOYSA-N 0.000 description 1
- BDOBLCDYWFTAGA-UHFFFAOYSA-N 3-[4-(2,5-difluorophenoxy)piperidin-1-yl]-3-oxo-n-(4-phenylphenyl)propanamide Chemical compound FC1=CC=C(F)C(OC2CCN(CC2)C(=O)CC(=O)NC=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 BDOBLCDYWFTAGA-UHFFFAOYSA-N 0.000 description 1
- RNTFBCPBIIECHG-UHFFFAOYSA-N 3-[4-(2,5-dimethylanilino)piperidin-1-yl]-3-oxo-n-(4-phenylphenyl)propanamide Chemical compound CC1=CC=C(C)C(NC2CCN(CC2)C(=O)CC(=O)NC=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 RNTFBCPBIIECHG-UHFFFAOYSA-N 0.000 description 1
- PVMAVVKCBJVOIS-UHFFFAOYSA-N 3-[4-(2-aminophenoxy)piperidin-1-yl]-3-oxo-n-(4-phenylphenyl)propanamide Chemical compound NC1=CC=CC=C1OC1CCN(C(=O)CC(=O)NC=2C=CC(=CC=2)C=2C=CC=CC=2)CC1 PVMAVVKCBJVOIS-UHFFFAOYSA-N 0.000 description 1
- LMTFETKUEHTGOQ-UHFFFAOYSA-N 3-[4-(2-bromoanilino)piperidin-1-yl]-3-oxo-n-(4-phenylphenyl)propanamide Chemical compound BrC1=CC=CC=C1NC1CCN(C(=O)CC(=O)NC=2C=CC(=CC=2)C=2C=CC=CC=2)CC1 LMTFETKUEHTGOQ-UHFFFAOYSA-N 0.000 description 1
- VAEWAVHUBWTGSH-UHFFFAOYSA-N 3-[4-(2-bromoanilino)piperidin-1-yl]-3-oxo-n-(6-phenylpyridin-3-yl)propanamide Chemical compound BrC1=CC=CC=C1NC1CCN(C(=O)CC(=O)NC=2C=NC(=CC=2)C=2C=CC=CC=2)CC1 VAEWAVHUBWTGSH-UHFFFAOYSA-N 0.000 description 1
- UUIGUCKWXJLEEO-UHFFFAOYSA-N 3-[4-(2-bromophenoxy)piperidin-1-yl]-3-oxo-n-(4-phenylphenyl)propanamide Chemical compound BrC1=CC=CC=C1OC1CCN(C(=O)CC(=O)NC=2C=CC(=CC=2)C=2C=CC=CC=2)CC1 UUIGUCKWXJLEEO-UHFFFAOYSA-N 0.000 description 1
- QGWBZLVWAMPTAZ-UHFFFAOYSA-N 3-[4-(2-bromophenyl)sulfanylpiperidin-1-yl]-3-oxo-n-(4-phenylphenyl)propanamide Chemical compound BrC1=CC=CC=C1SC1CCN(C(=O)CC(=O)NC=2C=CC(=CC=2)C=2C=CC=CC=2)CC1 QGWBZLVWAMPTAZ-UHFFFAOYSA-N 0.000 description 1
- XFCKOIMBVJSVGH-UHFFFAOYSA-N 3-[4-(2-bromophenyl)sulfanylpiperidin-1-yl]-3-oxo-n-(6-phenylpyridin-3-yl)propanamide Chemical compound BrC1=CC=CC=C1SC1CCN(C(=O)CC(=O)NC=2C=NC(=CC=2)C=2C=CC=CC=2)CC1 XFCKOIMBVJSVGH-UHFFFAOYSA-N 0.000 description 1
- GFIFKGLZEGKMTK-UHFFFAOYSA-N 3-[4-(2-chloro-5-fluorophenoxy)piperidin-1-yl]-3-oxo-n-(4-phenylphenyl)propanamide Chemical compound FC1=CC=C(Cl)C(OC2CCN(CC2)C(=O)CC(=O)NC=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 GFIFKGLZEGKMTK-UHFFFAOYSA-N 0.000 description 1
- BDNUNADUZOTDKX-UHFFFAOYSA-N 3-[4-(2-chloro-5-fluorophenoxy)piperidin-1-yl]-3-oxo-n-(5-phenylpyridin-2-yl)propanamide Chemical compound FC1=CC=C(Cl)C(OC2CCN(CC2)C(=O)CC(=O)NC=2N=CC(=CC=2)C=2C=CC=CC=2)=C1 BDNUNADUZOTDKX-UHFFFAOYSA-N 0.000 description 1
- XYMHUTNQALHNMM-UHFFFAOYSA-N 3-[4-(2-chloro-5-fluorophenoxy)piperidin-1-yl]-3-oxo-n-(6-phenylpyridin-3-yl)propanamide Chemical compound FC1=CC=C(Cl)C(OC2CCN(CC2)C(=O)CC(=O)NC=2C=NC(=CC=2)C=2C=CC=CC=2)=C1 XYMHUTNQALHNMM-UHFFFAOYSA-N 0.000 description 1
- WCAVUEHNHOEMSX-UHFFFAOYSA-N 3-[4-(2-chloroanilino)piperidin-1-yl]-3-oxo-n-(5-phenyl-1,3-thiazol-2-yl)propanamide Chemical compound ClC1=CC=CC=C1NC1CCN(C(=O)CC(=O)NC=2SC(=CN=2)C=2C=CC=CC=2)CC1 WCAVUEHNHOEMSX-UHFFFAOYSA-N 0.000 description 1
- LYZYOMIFKVOTRA-UHFFFAOYSA-N 3-[4-(2-chloroanilino)piperidin-1-yl]-3-oxo-n-(6-phenylpyridin-3-yl)propanamide Chemical compound ClC1=CC=CC=C1NC1CCN(C(=O)CC(=O)NC=2C=NC(=CC=2)C=2C=CC=CC=2)CC1 LYZYOMIFKVOTRA-UHFFFAOYSA-N 0.000 description 1
- BKKAQJXEIVTPGM-UHFFFAOYSA-N 3-[4-(2-chlorophenoxy)piperidin-1-yl]-3-oxo-n-(3-phenyl-1,2,4-thiadiazol-5-yl)propanamide Chemical compound ClC1=CC=CC=C1OC1CCN(C(=O)CC(=O)NC=2SN=C(N=2)C=2C=CC=CC=2)CC1 BKKAQJXEIVTPGM-UHFFFAOYSA-N 0.000 description 1
- DUIQSVQAWKATIR-UHFFFAOYSA-N 3-[4-(2-chlorophenoxy)piperidin-1-yl]-3-oxo-n-(5-phenyl-1,3-thiazol-2-yl)propanamide Chemical compound ClC1=CC=CC=C1OC1CCN(C(=O)CC(=O)NC=2SC(=CN=2)C=2C=CC=CC=2)CC1 DUIQSVQAWKATIR-UHFFFAOYSA-N 0.000 description 1
- BBFBPVOSCMRHAO-UHFFFAOYSA-N 3-[4-(2-chlorophenoxy)piperidin-1-yl]-3-oxo-n-(6-phenylpyridin-3-yl)propanamide Chemical compound ClC1=CC=CC=C1OC1CCN(C(=O)CC(=O)NC=2C=NC(=CC=2)C=2C=CC=CC=2)CC1 BBFBPVOSCMRHAO-UHFFFAOYSA-N 0.000 description 1
- HEDUOWWFDPUAQS-UHFFFAOYSA-N 3-[4-(2-chlorophenoxy)piperidin-1-yl]-n-[4-(1,2,4-oxadiazol-3-yl)phenyl]-3-oxopropanamide Chemical compound ClC1=CC=CC=C1OC1CCN(C(=O)CC(=O)NC=2C=CC(=CC=2)C2=NOC=N2)CC1 HEDUOWWFDPUAQS-UHFFFAOYSA-N 0.000 description 1
- ALWOANMIKBRIPL-UHFFFAOYSA-N 3-[4-(2-chlorophenyl)sulfanylpiperidin-1-yl]-3-oxo-n-(6-phenylpyridin-3-yl)propanamide Chemical compound ClC1=CC=CC=C1SC1CCN(C(=O)CC(=O)NC=2C=NC(=CC=2)C=2C=CC=CC=2)CC1 ALWOANMIKBRIPL-UHFFFAOYSA-N 0.000 description 1
- ODSKZIKVMYRKMD-UHFFFAOYSA-N 3-[4-(2-methylanilino)piperidin-1-yl]-3-oxo-n-(4-phenylphenyl)propanamide Chemical compound CC1=CC=CC=C1NC1CCN(C(=O)CC(=O)NC=2C=CC(=CC=2)C=2C=CC=CC=2)CC1 ODSKZIKVMYRKMD-UHFFFAOYSA-N 0.000 description 1
- CTKAWQIIQDLYMX-UHFFFAOYSA-N 3-[4-(2-methylanilino)piperidin-1-yl]-3-oxo-n-(6-phenylpyridin-3-yl)propanamide Chemical compound CC1=CC=CC=C1NC1CCN(C(=O)CC(=O)NC=2C=NC(=CC=2)C=2C=CC=CC=2)CC1 CTKAWQIIQDLYMX-UHFFFAOYSA-N 0.000 description 1
- DAWLJPOZGTYCCA-UHFFFAOYSA-N 3-[4-(2-nitrophenoxy)piperidin-1-yl]-3-oxo-n-(4-phenylphenyl)propanamide Chemical compound [O-][N+](=O)C1=CC=CC=C1OC1CCN(C(=O)CC(=O)NC=2C=CC(=CC=2)C=2C=CC=CC=2)CC1 DAWLJPOZGTYCCA-UHFFFAOYSA-N 0.000 description 1
- ANILIVZLWJKPRD-UHFFFAOYSA-N 3-[4-(2-tert-butylanilino)piperidin-1-yl]-3-oxo-n-(4-phenylphenyl)propanamide Chemical compound CC(C)(C)C1=CC=CC=C1NC1CCN(C(=O)CC(=O)NC=2C=CC(=CC=2)C=2C=CC=CC=2)CC1 ANILIVZLWJKPRD-UHFFFAOYSA-N 0.000 description 1
- QOADAQODWREKPQ-UHFFFAOYSA-N 3-[4-(3,4-dihydro-2h-quinolin-1-ylmethyl)phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(CN3C4=CC=CC=C4CCC3)=CC=2)=N1 QOADAQODWREKPQ-UHFFFAOYSA-N 0.000 description 1
- OXFGKEMWMUFPOP-UHFFFAOYSA-N 3-[4-(3-cyanophenoxy)piperidin-1-yl]-3-oxo-n-(4-phenylphenyl)propanamide Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1NC(=O)CC(=O)N(CC1)CCC1OC1=CC=CC(C#N)=C1 OXFGKEMWMUFPOP-UHFFFAOYSA-N 0.000 description 1
- CATCQUIDMCNBSP-UHFFFAOYSA-N 3-[4-(3-phenylpropoxy)phenyl]-1,2-oxazol-4-amine Chemical compound NC1=CON=C1C(C=C1)=CC=C1OCCCC1=CC=CC=C1 CATCQUIDMCNBSP-UHFFFAOYSA-N 0.000 description 1
- XJZOANAPLXKZBY-UHFFFAOYSA-N 3-[4-(benzimidazol-1-ylmethyl)phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(CN3C4=CC=CC=C4N=C3)=CC=2)=N1 XJZOANAPLXKZBY-UHFFFAOYSA-N 0.000 description 1
- DDMKIINOYUAVBB-UHFFFAOYSA-N 3-[4-(benzotriazol-1-ylmethyl)phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(CN3C4=CC=CC=C4N=N3)=CC=2)=N1 DDMKIINOYUAVBB-UHFFFAOYSA-N 0.000 description 1
- CDPAPRDDSRYLFS-UHFFFAOYSA-N 3-[4-(indazol-1-ylmethyl)phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(CN3C4=CC=CC=C4C=N3)=CC=2)=N1 CDPAPRDDSRYLFS-UHFFFAOYSA-N 0.000 description 1
- POGQKLNZNMFTAR-UHFFFAOYSA-N 3-[4-(indazol-2-ylmethyl)phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(CN3N=C4C=CC=CC4=C3)=CC=2)=N1 POGQKLNZNMFTAR-UHFFFAOYSA-N 0.000 description 1
- RUNYVGYJFPVBIU-UHFFFAOYSA-N 3-[4-(indol-1-ylmethyl)phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(CN3C4=CC=CC=C4C=C3)=CC=2)=N1 RUNYVGYJFPVBIU-UHFFFAOYSA-N 0.000 description 1
- APMFMSKGTDXRJJ-UHFFFAOYSA-N 3-[4-(pyridin-3-ylmethoxy)phenyl]-1,2-oxazol-4-amine Chemical compound NC1=CON=C1C(C=C1)=CC=C1OCC1=CC=CN=C1 APMFMSKGTDXRJJ-UHFFFAOYSA-N 0.000 description 1
- UJYKHFQAQQJDEO-UHFFFAOYSA-N 3-[4-[(2,6-dichlorophenyl)methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(OCC=3C(=CC=CC=3Cl)Cl)=CC=2)=N1 UJYKHFQAQQJDEO-UHFFFAOYSA-N 0.000 description 1
- RRXNRQZPVMFOIW-UHFFFAOYSA-N 3-[4-[(2,6-dimethylphenoxy)methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound CC1=CC=CC(C)=C1OCC1=CC=C(C2=NOC(=C2)C(N)=O)C=C1 RRXNRQZPVMFOIW-UHFFFAOYSA-N 0.000 description 1
- VGSRPZGVIIRYAN-UHFFFAOYSA-N 3-[4-[(2-bromophenyl)methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(OCC=3C(=CC=CC=3)Br)=CC=2)=N1 VGSRPZGVIIRYAN-UHFFFAOYSA-N 0.000 description 1
- XFXGPNZFICXPNO-UHFFFAOYSA-N 3-[4-[(2-chloro-4-methylsulfonylphenyl)methoxy]phenyl]-1,2-oxazol-4-amine Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1COC1=CC=C(C=2C(=CON=2)N)C=C1 XFXGPNZFICXPNO-UHFFFAOYSA-N 0.000 description 1
- ROHQBRLCEAMAMW-UHFFFAOYSA-N 3-[4-[(2-chloro-5-fluorophenyl)methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(OCC=3C(=CC=C(F)C=3)Cl)=CC=2)=N1 ROHQBRLCEAMAMW-UHFFFAOYSA-N 0.000 description 1
- QILVHPKYOZCISZ-UHFFFAOYSA-N 3-[4-[(2-chloro-6-fluorophenyl)methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(OCC=3C(=CC=CC=3F)Cl)=CC=2)=N1 QILVHPKYOZCISZ-UHFFFAOYSA-N 0.000 description 1
- JLSQEIOGQXEUQU-UHFFFAOYSA-N 3-[4-[(2-chlorophenyl)methoxy]phenyl]-1,2-oxazol-4-amine;hydrochloride Chemical compound Cl.NC1=CON=C1C(C=C1)=CC=C1OCC1=CC=CC=C1Cl JLSQEIOGQXEUQU-UHFFFAOYSA-N 0.000 description 1
- JQHZHAYBSQWUPW-UHFFFAOYSA-N 3-[4-[(2-chlorophenyl)methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(OCC=3C(=CC=CC=3)Cl)=CC=2)=N1 JQHZHAYBSQWUPW-UHFFFAOYSA-N 0.000 description 1
- RUCPYDMRWSJSRJ-UHFFFAOYSA-N 3-[4-[(2-chloropyridin-3-yl)methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(OCC=3C(=NC=CC=3)Cl)=CC=2)=N1 RUCPYDMRWSJSRJ-UHFFFAOYSA-N 0.000 description 1
- MAOXNLBTQNBATO-UHFFFAOYSA-N 3-[4-[(2-cyanophenoxy)methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(COC=3C(=CC=CC=3)C#N)=CC=2)=N1 MAOXNLBTQNBATO-UHFFFAOYSA-N 0.000 description 1
- VXKCEXJKGRPRNU-UHFFFAOYSA-N 3-[4-[(2-cyanophenyl)methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(OCC=3C(=CC=CC=3)C#N)=CC=2)=N1 VXKCEXJKGRPRNU-UHFFFAOYSA-N 0.000 description 1
- WQXVLPFQUAEYED-UHFFFAOYSA-N 3-[4-[(2-ethylphenoxy)methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound CCC1=CC=CC=C1OCC1=CC=C(C2=NOC(=C2)C(N)=O)C=C1 WQXVLPFQUAEYED-UHFFFAOYSA-N 0.000 description 1
- ZHOLTZJGFFRXOC-UHFFFAOYSA-N 3-[4-[(2-fluorophenoxy)methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(COC=3C(=CC=CC=3)F)=CC=2)=N1 ZHOLTZJGFFRXOC-UHFFFAOYSA-N 0.000 description 1
- KETYNQLECPILTK-UHFFFAOYSA-N 3-[4-[(2-fluorophenyl)methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(OCC=3C(=CC=CC=3)F)=CC=2)=N1 KETYNQLECPILTK-UHFFFAOYSA-N 0.000 description 1
- CDZSNQUYUGEICC-UHFFFAOYSA-N 3-[4-[(2-iodophenyl)methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(OCC=3C(=CC=CC=3)I)=CC=2)=N1 CDZSNQUYUGEICC-UHFFFAOYSA-N 0.000 description 1
- NKWVKBXUNBPEEY-UHFFFAOYSA-N 3-[4-[(2-methoxyphenoxy)methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound COC1=CC=CC=C1OCC1=CC=C(C2=NOC(=C2)C(N)=O)C=C1 NKWVKBXUNBPEEY-UHFFFAOYSA-N 0.000 description 1
- CVADAAIEZSWZGA-UHFFFAOYSA-N 3-[4-[(2-methoxyphenyl)methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound COC1=CC=CC=C1COC1=CC=C(C2=NOC(=C2)C(N)=O)C=C1 CVADAAIEZSWZGA-UHFFFAOYSA-N 0.000 description 1
- RXIVSLXUHXNWSU-UHFFFAOYSA-N 3-[4-[(2-methyl-2,3-dihydroindol-1-yl)methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound CC1CC2=CC=CC=C2N1CC(C=C1)=CC=C1C=1C=C(C(N)=O)ON=1 RXIVSLXUHXNWSU-UHFFFAOYSA-N 0.000 description 1
- HUZLSKXIQNTWEG-UHFFFAOYSA-N 3-[4-[(2-methylphenoxy)methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound CC1=CC=CC=C1OCC1=CC=C(C2=NOC(=C2)C(N)=O)C=C1 HUZLSKXIQNTWEG-UHFFFAOYSA-N 0.000 description 1
- ZJACNNMPIXFHDJ-UHFFFAOYSA-N 3-[4-[(2-methylphenyl)methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound CC1=CC=CC=C1COC1=CC=C(C2=NOC(=C2)C(N)=O)C=C1 ZJACNNMPIXFHDJ-UHFFFAOYSA-N 0.000 description 1
- DNNUHBKCPWAWMG-UHFFFAOYSA-N 3-[4-[(2-methylpyridin-3-yl)oxymethyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound CC1=NC=CC=C1OCC1=CC=C(C2=NOC(=C2)C(N)=O)C=C1 DNNUHBKCPWAWMG-UHFFFAOYSA-N 0.000 description 1
- TWCODBXRKKNEAL-UHFFFAOYSA-N 3-[4-[(2-methylsulfonylphenyl)methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound CS(=O)(=O)C1=CC=CC=C1COC1=CC=C(C2=NOC(=C2)C(N)=O)C=C1 TWCODBXRKKNEAL-UHFFFAOYSA-N 0.000 description 1
- PVGMVOBXMSHMEI-UHFFFAOYSA-N 3-[4-[(2-propan-2-ylphenoxy)methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound CC(C)C1=CC=CC=C1OCC1=CC=C(C2=NOC(=C2)C(N)=O)C=C1 PVGMVOBXMSHMEI-UHFFFAOYSA-N 0.000 description 1
- RFXSMIAGEBZIPP-UHFFFAOYSA-N 3-[4-[(2-tert-butylphenoxy)methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound CC(C)(C)C1=CC=CC=C1OCC1=CC=C(C2=NOC(=C2)C(N)=O)C=C1 RFXSMIAGEBZIPP-UHFFFAOYSA-N 0.000 description 1
- WWPWATFOLIDRII-UHFFFAOYSA-N 3-[4-[(3,4-dichlorophenyl)methoxy]phenyl]-1,2-oxazol-4-amine;hydrochloride Chemical compound Cl.NC1=CON=C1C(C=C1)=CC=C1OCC1=CC=C(Cl)C(Cl)=C1 WWPWATFOLIDRII-UHFFFAOYSA-N 0.000 description 1
- OOBLWRSYKQBWMP-UHFFFAOYSA-N 3-[4-[(3,4-difluorophenyl)methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(OCC=3C=C(F)C(F)=CC=3)=CC=2)=N1 OOBLWRSYKQBWMP-UHFFFAOYSA-N 0.000 description 1
- NMCPAXWGZMFADU-UHFFFAOYSA-N 3-[4-[(3,4-dimethylphenyl)methoxy]phenyl]-1,2-oxazol-4-amine;hydrochloride Chemical compound Cl.C1=C(C)C(C)=CC=C1COC1=CC=C(C=2C(=CON=2)N)C=C1 NMCPAXWGZMFADU-UHFFFAOYSA-N 0.000 description 1
- LEFHZCUOMZIWCY-UHFFFAOYSA-N 3-[4-[(3,4-dimethylphenyl)methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound C1=C(C)C(C)=CC=C1COC1=CC=C(C2=NOC(=C2)C(N)=O)C=C1 LEFHZCUOMZIWCY-UHFFFAOYSA-N 0.000 description 1
- JFHDTNTUVIRNRM-UHFFFAOYSA-N 3-[4-[(3,5-difluorophenyl)methoxy]phenyl]-1,2-oxazol-4-amine;hydrochloride Chemical compound Cl.NC1=CON=C1C(C=C1)=CC=C1OCC1=CC(F)=CC(F)=C1 JFHDTNTUVIRNRM-UHFFFAOYSA-N 0.000 description 1
- JVJOGGVTQJHDDA-UHFFFAOYSA-N 3-[4-[(3-chloro-2-methylphenoxy)methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound CC1=C(Cl)C=CC=C1OCC1=CC=C(C2=NOC(=C2)C(N)=O)C=C1 JVJOGGVTQJHDDA-UHFFFAOYSA-N 0.000 description 1
- HXSLUHIFRLUWNA-UHFFFAOYSA-N 3-[4-[(3-chlorophenyl)methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(OCC=3C=C(Cl)C=CC=3)=CC=2)=N1 HXSLUHIFRLUWNA-UHFFFAOYSA-N 0.000 description 1
- IZTMZHASFDZZMD-UHFFFAOYSA-N 3-[4-[(3-fluorophenyl)methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(OCC=3C=C(F)C=CC=3)=CC=2)=N1 IZTMZHASFDZZMD-UHFFFAOYSA-N 0.000 description 1
- GNFOQGVISLAKDC-UHFFFAOYSA-N 3-[4-[(3-methoxyphenoxy)methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound COC1=CC=CC(OCC=2C=CC(=CC=2)C2=NOC(=C2)C(N)=O)=C1 GNFOQGVISLAKDC-UHFFFAOYSA-N 0.000 description 1
- RSGPUHOVASQQTG-UHFFFAOYSA-N 3-[4-[(3-methylphenoxy)methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound CC1=CC=CC(OCC=2C=CC(=CC=2)C2=NOC(=C2)C(N)=O)=C1 RSGPUHOVASQQTG-UHFFFAOYSA-N 0.000 description 1
- RQPRAFMRBOYPSR-UHFFFAOYSA-N 3-[4-[(3-methylpyridin-2-yl)oxymethyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound CC1=CC=CN=C1OCC1=CC=C(C2=NOC(=C2)C(N)=O)C=C1 RQPRAFMRBOYPSR-UHFFFAOYSA-N 0.000 description 1
- JZQVIUAHJGRYAD-UHFFFAOYSA-N 3-[4-[(4-chlorophenyl)methoxy]phenyl]-1,2-oxazol-4-amine Chemical compound NC1=CON=C1C(C=C1)=CC=C1OCC1=CC=C(Cl)C=C1 JZQVIUAHJGRYAD-UHFFFAOYSA-N 0.000 description 1
- TZMIBPMEYVOBLZ-UHFFFAOYSA-N 3-[4-[(4-ethylsulfonylphenyl)methoxy]phenyl]-1,2-oxazol-4-amine Chemical compound C1=CC(S(=O)(=O)CC)=CC=C1COC1=CC=C(C=2C(=CON=2)N)C=C1 TZMIBPMEYVOBLZ-UHFFFAOYSA-N 0.000 description 1
- BYBIBKHPIKPGEZ-UHFFFAOYSA-N 3-[4-[(4-fluoro-2-methylphenoxy)methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound CC1=CC(F)=CC=C1OCC1=CC=C(C2=NOC(=C2)C(N)=O)C=C1 BYBIBKHPIKPGEZ-UHFFFAOYSA-N 0.000 description 1
- KOHKBEFWLUVLIQ-UHFFFAOYSA-N 3-[4-[(4-fluorophenyl)methoxy]phenyl]-1,2-oxazol-4-amine Chemical compound NC1=CON=C1C(C=C1)=CC=C1OCC1=CC=C(F)C=C1 KOHKBEFWLUVLIQ-UHFFFAOYSA-N 0.000 description 1
- OKQRNRVSMHCGIW-UHFFFAOYSA-N 3-[4-[(4-iodophenyl)methoxy]phenyl]-1,2-oxazol-4-amine Chemical compound NC1=CON=C1C(C=C1)=CC=C1OCC1=CC=C(I)C=C1 OKQRNRVSMHCGIW-UHFFFAOYSA-N 0.000 description 1
- GEPIWWOOEPPACY-UHFFFAOYSA-N 3-[4-[(4-methoxyphenoxy)methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound C1=CC(OC)=CC=C1OCC1=CC=C(C2=NOC(=C2)C(N)=O)C=C1 GEPIWWOOEPPACY-UHFFFAOYSA-N 0.000 description 1
- FASJQRNGZGPNGM-UHFFFAOYSA-N 3-[4-[(4-methoxyphenyl)methoxy]phenyl]-1,2-oxazol-4-amine Chemical compound C1=CC(OC)=CC=C1COC1=CC=C(C=2C(=CON=2)N)C=C1 FASJQRNGZGPNGM-UHFFFAOYSA-N 0.000 description 1
- SAXHZGVYURFDFP-UHFFFAOYSA-N 3-[4-[(4-methylindol-1-yl)methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound C1=CC=2C(C)=CC=CC=2N1CC(C=C1)=CC=C1C=1C=C(C(N)=O)ON=1 SAXHZGVYURFDFP-UHFFFAOYSA-N 0.000 description 1
- LNLQCYSIHYDHAK-UHFFFAOYSA-N 3-[4-[(4-methylphenyl)methoxy]phenyl]-1,2-oxazol-4-amine;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1COC1=CC=C(C=2C(=CON=2)N)C=C1 LNLQCYSIHYDHAK-UHFFFAOYSA-N 0.000 description 1
- OYWJROVBSAQEET-UHFFFAOYSA-N 3-[4-[(4-methylsulfanylphenyl)methoxy]phenyl]-1,2-oxazol-4-amine Chemical compound C1=CC(SC)=CC=C1COC1=CC=C(C=2C(=CON=2)N)C=C1 OYWJROVBSAQEET-UHFFFAOYSA-N 0.000 description 1
- MKJVNOTZSOPVGS-UHFFFAOYSA-N 3-[4-[(4-methylsulfonylanilino)methyl]phenyl]-1,2-oxazol-4-amine;hydrochloride Chemical compound Cl.C1=CC(S(=O)(=O)C)=CC=C1NCC1=CC=C(C=2C(=CON=2)N)C=C1 MKJVNOTZSOPVGS-UHFFFAOYSA-N 0.000 description 1
- UJJASKTZBPRJKK-UHFFFAOYSA-N 3-[4-[(4-methylsulfonylphenyl)methoxy]phenyl]-1,2-oxazol-4-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1COC1=CC=C(C=2C(=CON=2)N)C=C1 UJJASKTZBPRJKK-UHFFFAOYSA-N 0.000 description 1
- LEQWWRKHHINZKO-UHFFFAOYSA-N 3-[4-[(4-methylsulfonylphenyl)methoxy]phenyl]-1,2-oxazol-4-amine;hydrochloride Chemical compound Cl.C1=CC(S(=O)(=O)C)=CC=C1COC1=CC=C(C=2C(=CON=2)N)C=C1 LEQWWRKHHINZKO-UHFFFAOYSA-N 0.000 description 1
- YGIVWRXPDFPOBN-UHFFFAOYSA-N 3-[4-[(4-nitrophenyl)methoxy]phenyl]-1,2-oxazol-4-amine;hydrochloride Chemical compound Cl.NC1=CON=C1C(C=C1)=CC=C1OCC1=CC=C([N+]([O-])=O)C=C1 YGIVWRXPDFPOBN-UHFFFAOYSA-N 0.000 description 1
- VFLQCJVCVHBQMQ-UHFFFAOYSA-N 3-[4-[(4-propan-2-ylphenyl)methoxy]phenyl]-1,2-oxazol-4-amine Chemical compound C1=CC(C(C)C)=CC=C1COC1=CC=C(C=2C(=CON=2)N)C=C1 VFLQCJVCVHBQMQ-UHFFFAOYSA-N 0.000 description 1
- PPKFDCJDQJIRDZ-UHFFFAOYSA-N 3-[4-[(5-chloro-2-methylphenoxy)methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound CC1=CC=C(Cl)C=C1OCC1=CC=C(C2=NOC(=C2)C(N)=O)C=C1 PPKFDCJDQJIRDZ-UHFFFAOYSA-N 0.000 description 1
- IZZUKVCWUKCURE-UHFFFAOYSA-N 3-[4-[(5-fluoro-2-methylphenoxy)methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound CC1=CC=C(F)C=C1OCC1=CC=C(C2=NOC(=C2)C(N)=O)C=C1 IZZUKVCWUKCURE-UHFFFAOYSA-N 0.000 description 1
- XULPUIHYIIHXQW-UHFFFAOYSA-N 3-[4-[2-(4-methylsulfonylphenyl)ethyl]phenyl]-1,2-oxazol-4-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1CCC1=CC=C(C=2C(=CON=2)N)C=C1 XULPUIHYIIHXQW-UHFFFAOYSA-N 0.000 description 1
- PWXINJXTULZSLS-UHFFFAOYSA-N 3-[4-[[2-(trifluoromethoxy)phenoxy]methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(COC=3C(=CC=CC=3)OC(F)(F)F)=CC=2)=N1 PWXINJXTULZSLS-UHFFFAOYSA-N 0.000 description 1
- LWCUFJDIDKCMPP-UHFFFAOYSA-N 3-[4-[[2-(trifluoromethoxy)phenyl]methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(OCC=3C(=CC=CC=3)OC(F)(F)F)=CC=2)=N1 LWCUFJDIDKCMPP-UHFFFAOYSA-N 0.000 description 1
- ILKMBZDVBWGLEN-UHFFFAOYSA-N 3-[4-[[2-(trifluoromethyl)phenoxy]methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(COC=3C(=CC=CC=3)C(F)(F)F)=CC=2)=N1 ILKMBZDVBWGLEN-UHFFFAOYSA-N 0.000 description 1
- KKJAUYFTYPDEFQ-UHFFFAOYSA-N 3-[4-[[2-(trifluoromethyl)phenyl]methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(OCC=3C(=CC=CC=3)C(F)(F)F)=CC=2)=N1 KKJAUYFTYPDEFQ-UHFFFAOYSA-N 0.000 description 1
- OYVHSKWWSGSAIR-UHFFFAOYSA-N 3-[4-[[2-(trifluoromethylsulfanyl)phenyl]methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(OCC=3C(=CC=CC=3)SC(F)(F)F)=CC=2)=N1 OYVHSKWWSGSAIR-UHFFFAOYSA-N 0.000 description 1
- IHQWUJVYTHRJGN-UHFFFAOYSA-N 3-[4-[[2-(trifluoromethylsulfinyl)phenyl]methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(OCC=3C(=CC=CC=3)S(=O)C(F)(F)F)=CC=2)=N1 IHQWUJVYTHRJGN-UHFFFAOYSA-N 0.000 description 1
- HSHOURBGTONSMS-UHFFFAOYSA-N 3-[4-[[3-(trifluoromethoxy)phenyl]methoxy]phenyl]-1,2-oxazol-4-amine;hydrochloride Chemical compound Cl.NC1=CON=C1C(C=C1)=CC=C1OCC1=CC=CC(OC(F)(F)F)=C1 HSHOURBGTONSMS-UHFFFAOYSA-N 0.000 description 1
- IIBXLWHNQWXZJH-UHFFFAOYSA-N 3-[4-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC(OCC=3C=C(C=CC=3)C(F)(F)F)=CC=2)=N1 IIBXLWHNQWXZJH-UHFFFAOYSA-N 0.000 description 1
- PDQIYEXGURUVEH-UHFFFAOYSA-N 3-[4-[[4-(benzenesulfonyl)phenyl]methoxy]phenyl]-1,2-oxazol-4-amine Chemical compound NC1=CON=C1C(C=C1)=CC=C1OCC1=CC=C(S(=O)(=O)C=2C=CC=CC=2)C=C1 PDQIYEXGURUVEH-UHFFFAOYSA-N 0.000 description 1
- JAAYGGMCIHHNCE-UHFFFAOYSA-N 3-[4-[[4-(trifluoromethoxy)phenyl]methoxy]phenyl]-1,2-oxazol-4-amine;hydrochloride Chemical compound Cl.NC1=CON=C1C(C=C1)=CC=C1OCC1=CC=C(OC(F)(F)F)C=C1 JAAYGGMCIHHNCE-UHFFFAOYSA-N 0.000 description 1
- QOMJMYSTHPJDBW-UHFFFAOYSA-N 3-[4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]-1,2-oxazol-4-amine;hydrochloride Chemical compound Cl.NC1=CON=C1C(C=C1)=CC=C1OCC1=CC=C(C(F)(F)F)C=C1 QOMJMYSTHPJDBW-UHFFFAOYSA-N 0.000 description 1
- FYWQTMKSYJGXPU-UHFFFAOYSA-N 3-[4-[[4-(trifluoromethylsulfanyl)phenyl]methoxy]phenyl]-1,2-oxazol-4-amine Chemical compound NC1=CON=C1C(C=C1)=CC=C1OCC1=CC=C(SC(F)(F)F)C=C1 FYWQTMKSYJGXPU-UHFFFAOYSA-N 0.000 description 1
- QHPVHZFPPXSDKS-UHFFFAOYSA-N 3-[5-(2-phenylethoxy)pyridin-2-yl]-1,2-oxazol-4-amine Chemical compound NC1=CON=C1C(N=C1)=CC=C1OCCC1=CC=CC=C1 QHPVHZFPPXSDKS-UHFFFAOYSA-N 0.000 description 1
- DTEYXFXPLZRCQP-UHFFFAOYSA-N 3-[5-[(2-chlorophenyl)methoxy]pyridin-2-yl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2N=CC(OCC=3C(=CC=CC=3)Cl)=CC=2)=N1 DTEYXFXPLZRCQP-UHFFFAOYSA-N 0.000 description 1
- NUAYAXBWUZEHAZ-UHFFFAOYSA-N 3-[5-[(4-methylsulfonylphenyl)methoxy]pyridin-2-yl]-1,2-oxazol-4-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1COC1=CC=C(C=2C(=CON=2)N)N=C1 NUAYAXBWUZEHAZ-UHFFFAOYSA-N 0.000 description 1
- INNPJMJARRJPDM-UHFFFAOYSA-N 3-[5-[[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]carbamoyl]-1h-pyrazol-3-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C2=NNC(=C2)C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(C=CC=2)C(F)(F)F)=C1 INNPJMJARRJPDM-UHFFFAOYSA-N 0.000 description 1
- ZAKHNXLNGJNSBO-UHFFFAOYSA-N 3-[[4-(4-amino-1,2-oxazol-3-yl)phenoxy]methyl]benzonitrile;hydrochloride Chemical compound Cl.NC1=CON=C1C(C=C1)=CC=C1OCC1=CC=CC(C#N)=C1 ZAKHNXLNGJNSBO-UHFFFAOYSA-N 0.000 description 1
- MJQWEOVOAFYGBS-UHFFFAOYSA-N 3-oxo-n-(4-phenylphenyl)-3-[4-(3,4,5-trifluorophenoxy)piperidin-1-yl]propanamide Chemical compound FC1=C(F)C(F)=CC(OC2CCN(CC2)C(=O)CC(=O)NC=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 MJQWEOVOAFYGBS-UHFFFAOYSA-N 0.000 description 1
- NXRWUHBEAUHMOQ-UHFFFAOYSA-N 3-oxo-n-(6-phenylpyridin-3-yl)-3-[4-[2-(trifluoromethyl)anilino]piperidin-1-yl]propanamide Chemical compound FC(F)(F)C1=CC=CC=C1NC1CCN(C(=O)CC(=O)NC=2C=NC(=CC=2)C=2C=CC=CC=2)CC1 NXRWUHBEAUHMOQ-UHFFFAOYSA-N 0.000 description 1
- GYELPMCREZETQR-UHFFFAOYSA-N 3-oxo-n-(6-phenylpyridin-3-yl)-3-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]propanamide Chemical compound FC(F)(F)C1=CC=CC=C1OC1CCN(C(=O)CC(=O)NC=2C=NC(=CC=2)C=2C=CC=CC=2)CC1 GYELPMCREZETQR-UHFFFAOYSA-N 0.000 description 1
- OVJSTHBDUBWNDW-UHFFFAOYSA-N 3-oxo-n-(6-phenylpyridin-3-yl)-3-[4-[2-(trifluoromethyl)phenyl]sulfanylpiperidin-1-yl]propanamide Chemical compound FC(F)(F)C1=CC=CC=C1SC1CCN(C(=O)CC(=O)NC=2C=NC(=CC=2)C=2C=CC=CC=2)CC1 OVJSTHBDUBWNDW-UHFFFAOYSA-N 0.000 description 1
- LBCDTCUUCMOOGC-UHFFFAOYSA-N 4-(2-oxopyrrolidin-1-yl)-n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]benzamide Chemical compound FC(F)(F)C1=CC=CC(OC2CCN(CC2)C(=O)CNC(=O)C=2C=CC(=CC=2)N2C(CCC2)=O)=C1 LBCDTCUUCMOOGC-UHFFFAOYSA-N 0.000 description 1
- FMVIGRLQPSJDOA-UHFFFAOYSA-N 4-[[4-(4-amino-1,2-oxazol-3-yl)phenoxy]methyl]benzonitrile;hydrochloride Chemical compound Cl.NC1=CON=C1C(C=C1)=CC=C1OCC1=CC=C(C#N)C=C1 FMVIGRLQPSJDOA-UHFFFAOYSA-N 0.000 description 1
- STCWFUZPIZNCNS-UHFFFAOYSA-N 4-anilino-n-[2-[4-(2-bromoanilino)piperidin-1-yl]-2-oxoethyl]benzamide Chemical compound BrC1=CC=CC=C1NC1CCN(C(=O)CNC(=O)C=2C=CC(NC=3C=CC=CC=3)=CC=2)CC1 STCWFUZPIZNCNS-UHFFFAOYSA-N 0.000 description 1
- IIVSFXAFASMDEP-UHFFFAOYSA-N 4-anilino-n-[2-[4-(2-bromophenoxy)piperidin-1-yl]-2-oxoethyl]benzamide Chemical compound BrC1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C=2C=CC(NC=3C=CC=CC=3)=CC=2)CC1 IIVSFXAFASMDEP-UHFFFAOYSA-N 0.000 description 1
- KQJNEJZQJRLPPB-UHFFFAOYSA-N 4-anilino-n-[2-[4-(2-chloroanilino)piperidin-1-yl]-2-oxoethyl]benzamide Chemical compound ClC1=CC=CC=C1NC1CCN(C(=O)CNC(=O)C=2C=CC(NC=3C=CC=CC=3)=CC=2)CC1 KQJNEJZQJRLPPB-UHFFFAOYSA-N 0.000 description 1
- HDPDYSKMTICOON-UHFFFAOYSA-N 4-anilino-n-[2-[4-[n-methyl-2-(trifluoromethyl)anilino]piperidin-1-yl]-2-oxoethyl]benzamide Chemical compound C=1C=CC=C(C(F)(F)F)C=1N(C)C(CC1)CCN1C(=O)CNC(=O)C(C=C1)=CC=C1NC1=CC=CC=C1 HDPDYSKMTICOON-UHFFFAOYSA-N 0.000 description 1
- YEMIVSHSZFWHFW-UHFFFAOYSA-N 4-anilino-n-[2-oxo-2-[4-[2-(trifluoromethyl)anilino]piperidin-1-yl]ethyl]benzamide Chemical compound FC(F)(F)C1=CC=CC=C1NC1CCN(C(=O)CNC(=O)C=2C=CC(NC=3C=CC=CC=3)=CC=2)CC1 YEMIVSHSZFWHFW-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- ZBJSDMAUTOHYER-UHFFFAOYSA-N 5-(2-fluorophenyl)-n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(C=CC=2)C(F)(F)F)=NO1 ZBJSDMAUTOHYER-UHFFFAOYSA-N 0.000 description 1
- MMSWRFMDGRLEHB-UHFFFAOYSA-N 5-(2-hydroxyphenyl)-N-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-1,2-oxazole-3-carboxamide Chemical compound OC1=CC=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(C=CC=2)C(F)(F)F)=NO1 MMSWRFMDGRLEHB-UHFFFAOYSA-N 0.000 description 1
- QFXGCVLAIXZNFP-UHFFFAOYSA-N 5-(3-fluorophenyl)-n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=CC(C=2ON=C(C=2)C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(C=CC=2)C(F)(F)F)=C1 QFXGCVLAIXZNFP-UHFFFAOYSA-N 0.000 description 1
- BPKQAZUPMXCHJJ-UHFFFAOYSA-N 5-(3-hydroxyphenyl)-n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-1,2-oxazole-3-carboxamide Chemical compound OC1=CC=CC(C=2ON=C(C=2)C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(C=CC=2)C(F)(F)F)=C1 BPKQAZUPMXCHJJ-UHFFFAOYSA-N 0.000 description 1
- CRRRVFBIDRSTBJ-UHFFFAOYSA-N 5-(4-fluorophenyl)-n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-1,2-oxazole-3-carboxamide Chemical compound C1=CC(F)=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(C=CC=2)C(F)(F)F)=NO1 CRRRVFBIDRSTBJ-UHFFFAOYSA-N 0.000 description 1
- SIIDHBMHAXKCMS-UHFFFAOYSA-N 5-(4-hydroxyphenyl)-N-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-1,2-oxazole-3-carboxamide Chemical compound C1=CC(O)=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(C=CC=2)C(F)(F)F)=NO1 SIIDHBMHAXKCMS-UHFFFAOYSA-N 0.000 description 1
- GYIXQBMJJZNZJW-UHFFFAOYSA-N 5-(5-chlorothiophen-2-yl)-1h-pyrazole-3-carboxylic acid Chemical compound N1N=C(C(=O)O)C=C1C1=CC=C(Cl)S1 GYIXQBMJJZNZJW-UHFFFAOYSA-N 0.000 description 1
- KHBXBSQVQQTXSO-UHFFFAOYSA-N 5-(5-chlorothiophen-2-yl)-n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-1h-pyrazole-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(OC2CCN(CC2)C(=O)CNC(=O)C2=NNC(=C2)C=2SC(Cl)=CC=2)=C1 KHBXBSQVQQTXSO-UHFFFAOYSA-N 0.000 description 1
- RKBJFNOLXGXLIL-UHFFFAOYSA-N 5-methyl-3-[4-[(4-methylsulfonylphenyl)methoxy]phenyl]-1,2-oxazol-4-amine Chemical compound NC1=C(C)ON=C1C(C=C1)=CC=C1OCC1=CC=C(S(C)(=O)=O)C=C1 RKBJFNOLXGXLIL-UHFFFAOYSA-N 0.000 description 1
- AMBDRXRCOGOEHY-UHFFFAOYSA-N 6-anilino-n-[2-[4-(2-chloroanilino)piperidin-1-yl]-2-oxoethyl]pyridine-3-carboxamide Chemical compound ClC1=CC=CC=C1NC1CCN(C(=O)CNC(=O)C=2C=NC(NC=3C=CC=CC=3)=CC=2)CC1 AMBDRXRCOGOEHY-UHFFFAOYSA-N 0.000 description 1
- CVCPMHBFYCTWQH-UHFFFAOYSA-N 6-anilino-n-[2-[4-(2-chlorophenoxy)piperidin-1-yl]-2-oxoethyl]pyridine-3-carboxamide Chemical compound ClC1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C=2C=NC(NC=3C=CC=CC=3)=CC=2)CC1 CVCPMHBFYCTWQH-UHFFFAOYSA-N 0.000 description 1
- 108010060219 Apolipoprotein E2 Proteins 0.000 description 1
- 108010060215 Apolipoprotein E3 Proteins 0.000 description 1
- 102000008128 Apolipoprotein E3 Human genes 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000771674 Homo sapiens Apolipoprotein E Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JJQRBLLPQYFXHQ-UHFFFAOYSA-N N-[2-[4-(2-chloroanilino)piperidin-1-yl]-2-oxoethyl]-3-(2-hydroxyphenyl)-1H-pyrazole-5-carboxamide Chemical class OC1=CC=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)NC=2C(=CC=CC=2)Cl)=NN1 JJQRBLLPQYFXHQ-UHFFFAOYSA-N 0.000 description 1
- SYMQLTABFSPTCQ-UHFFFAOYSA-N N-[2-[4-(2-chloroanilino)piperidin-1-yl]-2-oxoethyl]-3-(4-hydroxyphenyl)-1H-pyrazole-5-carboxamide Chemical class C1=CC(O)=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)NC=2C(=CC=CC=2)Cl)=NN1 SYMQLTABFSPTCQ-UHFFFAOYSA-N 0.000 description 1
- RWKMMQRQJJXJNX-UHFFFAOYSA-N N-[2-[4-(2-chloroanilino)piperidin-1-yl]-2-oxoethyl]-5-(2-hydroxyphenyl)-1,2-oxazole-3-carboxamide Chemical class OC1=CC=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)NC=2C(=CC=CC=2)Cl)=NO1 RWKMMQRQJJXJNX-UHFFFAOYSA-N 0.000 description 1
- AAEDOLFUSSQVFG-UHFFFAOYSA-N N-[2-[4-(2-chloroanilino)piperidin-1-yl]-2-oxoethyl]-5-(2-hydroxyphenyl)-1-methylpyrazole-3-carboxamide Chemical compound CN1N=C(C(=O)NCC(=O)N2CCC(CC2)NC=2C(=CC=CC=2)Cl)C=C1C1=CC=CC=C1O AAEDOLFUSSQVFG-UHFFFAOYSA-N 0.000 description 1
- KDYWKUHLQPGVBV-UHFFFAOYSA-N N-[2-[4-(2-chlorophenoxy)piperidin-1-yl]-2-oxoethyl]-3-(2-hydroxyphenyl)-1H-pyrazole-5-carboxamide Chemical class OC1=CC=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)OC=2C(=CC=CC=2)Cl)=NN1 KDYWKUHLQPGVBV-UHFFFAOYSA-N 0.000 description 1
- BVXVSCNTHVGDRU-UHFFFAOYSA-N N-[2-[4-(2-chlorophenoxy)piperidin-1-yl]-2-oxoethyl]-5-(2-hydroxyphenyl)-1,2-oxazole-3-carboxamide Chemical class OC1=CC=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)OC=2C(=CC=CC=2)Cl)=NO1 BVXVSCNTHVGDRU-UHFFFAOYSA-N 0.000 description 1
- 208000024571 Pick disease Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 101150048395 SCD gene Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 125000005120 alkyl cycloalkyl alkyl group Chemical group 0.000 description 1
- WJWWCJJDDLCVCA-UHFFFAOYSA-N amino carbonofluoridate Chemical compound NOC(F)=O WJWWCJJDDLCVCA-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 229910021386 carbon form Inorganic materials 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 description 1
- 102000053020 human ApoE Human genes 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- RUZIJPCFVGHFKU-UHFFFAOYSA-N methyl 4-[[4-(4-amino-1,2-oxazol-3-yl)phenoxy]methyl]benzoate;hydrochloride Chemical compound Cl.C1=CC(C(=O)OC)=CC=C1COC1=CC=C(C=2C(=CON=2)N)C=C1 RUZIJPCFVGHFKU-UHFFFAOYSA-N 0.000 description 1
- BMDOFLWBTKVSHQ-UHFFFAOYSA-N methyl 4-methyl-3-[1-[2-[(3-phenyl-1h-pyrazole-5-carbonyl)amino]acetyl]piperidin-4-yl]oxybenzoate Chemical compound COC(=O)C1=CC=C(C)C(OC2CCN(CC2)C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)=C1 BMDOFLWBTKVSHQ-UHFFFAOYSA-N 0.000 description 1
- FCWRLRQZBFXHQF-UHFFFAOYSA-N n-[2-[3-(2,5-difluorophenoxy)pyrrolidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound FC1=CC=C(F)C(OC2CN(CC2)C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)=C1 FCWRLRQZBFXHQF-UHFFFAOYSA-N 0.000 description 1
- ZQYOWKMOIKSRPB-UHFFFAOYSA-N n-[2-[3-(2,5-difluorophenoxy)pyrrolidin-1-yl]-2-oxoethyl]-5-phenyl-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=C(F)C(OC2CN(CC2)C(=O)CNC(=O)C2=NOC(=C2)C=2C=CC=CC=2)=C1 ZQYOWKMOIKSRPB-UHFFFAOYSA-N 0.000 description 1
- LOYSBUAAPHUHHS-UHFFFAOYSA-N n-[2-[3-(2-chlorophenoxy)azetidin-1-yl]-2-oxoethyl]-1-phenylimidazole-4-carboxamide Chemical compound ClC1=CC=CC=C1OC1CN(C(=O)CNC(=O)C=2N=CN(C=2)C=2C=CC=CC=2)C1 LOYSBUAAPHUHHS-UHFFFAOYSA-N 0.000 description 1
- DPJVZGMGBCZHKX-UHFFFAOYSA-N n-[2-[3-(2-chlorophenoxy)azetidin-1-yl]-2-oxoethyl]-1-pyridin-3-yltriazole-4-carboxamide Chemical compound ClC1=CC=CC=C1OC1CN(C(=O)CNC(=O)C=2N=NN(C=2)C=2C=NC=CC=2)C1 DPJVZGMGBCZHKX-UHFFFAOYSA-N 0.000 description 1
- FYTDEWMBDVTJSO-UHFFFAOYSA-N n-[2-[3-(2-chlorophenoxy)azetidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound ClC1=CC=CC=C1OC1CN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)C1 FYTDEWMBDVTJSO-UHFFFAOYSA-N 0.000 description 1
- RJNXNBAZWVMZQW-UHFFFAOYSA-N n-[2-[3-(2-chlorophenoxy)pyrrolidin-1-yl]-2-oxoethyl]-1-phenylimidazole-4-carboxamide Chemical compound ClC1=CC=CC=C1OC1CN(C(=O)CNC(=O)C=2N=CN(C=2)C=2C=CC=CC=2)CC1 RJNXNBAZWVMZQW-UHFFFAOYSA-N 0.000 description 1
- DNSOZZOLYMPPRJ-UHFFFAOYSA-N n-[2-[3-(2-chlorophenoxy)pyrrolidin-1-yl]-2-oxoethyl]-1-pyridin-3-yltriazole-4-carboxamide Chemical compound ClC1=CC=CC=C1OC1CN(C(=O)CNC(=O)C=2N=NN(C=2)C=2C=NC=CC=2)CC1 DNSOZZOLYMPPRJ-UHFFFAOYSA-N 0.000 description 1
- UNJQURJNOIJTTH-UHFFFAOYSA-N n-[2-[3-(5-cyano-2-methylphenoxy)azetidin-1-yl]-2-oxoethyl]-1-phenylimidazole-4-carboxamide Chemical compound CC1=CC=C(C#N)C=C1OC1CN(C(=O)CNC(=O)C=2N=CN(C=2)C=2C=CC=CC=2)C1 UNJQURJNOIJTTH-UHFFFAOYSA-N 0.000 description 1
- WZEUNJRSKJIIHQ-UHFFFAOYSA-N n-[2-[3-(5-cyano-2-methylphenoxy)azetidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound CC1=CC=C(C#N)C=C1OC1CN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)C1 WZEUNJRSKJIIHQ-UHFFFAOYSA-N 0.000 description 1
- CDLNZLXUBGTMNU-UHFFFAOYSA-N n-[2-[3-[3-fluoro-5-(trifluoromethyl)phenoxy]azetidin-1-yl]-2-oxoethyl]-1-phenylimidazole-4-carboxamide Chemical class FC(F)(F)C1=CC(F)=CC(OC2CN(C2)C(=O)CNC(=O)C=2N=CN(C=2)C=2C=CC=CC=2)=C1 CDLNZLXUBGTMNU-UHFFFAOYSA-N 0.000 description 1
- AUWAPZKUUGAMSO-UHFFFAOYSA-N n-[2-[3-[3-fluoro-5-(trifluoromethyl)phenoxy]azetidin-1-yl]-2-oxoethyl]-1-pyridin-3-yltriazole-4-carboxamide Chemical compound FC(F)(F)C1=CC(F)=CC(OC2CN(C2)C(=O)CNC(=O)C=2N=NN(C=2)C=2C=NC=CC=2)=C1 AUWAPZKUUGAMSO-UHFFFAOYSA-N 0.000 description 1
- BZDPLIAACVTKNV-UHFFFAOYSA-N n-[2-[3-[3-fluoro-5-(trifluoromethyl)phenoxy]azetidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical class FC(F)(F)C1=CC(F)=CC(OC2CN(C2)C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)=C1 BZDPLIAACVTKNV-UHFFFAOYSA-N 0.000 description 1
- AAIDONPBNQPBDS-UHFFFAOYSA-N n-[2-[4-(2,3-dimethylanilino)piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound CC1=CC=CC(NC2CCN(CC2)C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)=C1C AAIDONPBNQPBDS-UHFFFAOYSA-N 0.000 description 1
- LYIMNBGPMOUQRO-UHFFFAOYSA-N n-[2-[4-(2,4-difluoroanilino)piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound FC1=CC(F)=CC=C1NC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 LYIMNBGPMOUQRO-UHFFFAOYSA-N 0.000 description 1
- XPLOYTMHUQOYEC-UHFFFAOYSA-N n-[2-[4-(2,4-dimethylanilino)piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound CC1=CC(C)=CC=C1NC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 XPLOYTMHUQOYEC-UHFFFAOYSA-N 0.000 description 1
- OGWBHUYCALEIPO-UHFFFAOYSA-N n-[2-[4-(2-acetylphenoxy)piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound CC(=O)C1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 OGWBHUYCALEIPO-UHFFFAOYSA-N 0.000 description 1
- GZYRLKDYASGKCQ-UHFFFAOYSA-N n-[2-[4-(2-adamantylamino)piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound C1CC(NC2C3CC4CC(C3)CC2C4)CCN1C(=O)CNC(=O)C(=NN1)C=C1C1=CC=CC=C1 GZYRLKDYASGKCQ-UHFFFAOYSA-N 0.000 description 1
- NXRUWEJJNNUHFW-UHFFFAOYSA-N n-[2-[4-(2-aminophenoxy)piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound NC1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 NXRUWEJJNNUHFW-UHFFFAOYSA-N 0.000 description 1
- BQKDBUXHTUHWIU-UHFFFAOYSA-N n-[2-[4-(2-bromo-n-methylanilino)piperidin-1-yl]-2-oxoethyl]-4-phenylbenzamide Chemical compound C=1C=CC=C(Br)C=1N(C)C(CC1)CCN1C(=O)CNC(=O)C(C=C1)=CC=C1C1=CC=CC=C1 BQKDBUXHTUHWIU-UHFFFAOYSA-N 0.000 description 1
- KFQKKPOQRLXIFO-UHFFFAOYSA-N n-[2-[4-(2-bromo-n-methylanilino)piperidin-1-yl]-2-oxoethyl]-5-phenyl-1,2-oxazole-3-carboxamide Chemical compound C=1C=CC=C(Br)C=1N(C)C(CC1)CCN1C(=O)CNC(=O)C(=NO1)C=C1C1=CC=CC=C1 KFQKKPOQRLXIFO-UHFFFAOYSA-N 0.000 description 1
- QIIFXXGOKSHPRE-UHFFFAOYSA-N n-[2-[4-(2-bromoanilino)piperidin-1-yl]-2-oxoethyl]-4-phenylbenzamide Chemical compound BrC1=CC=CC=C1NC1CCN(C(=O)CNC(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)CC1 QIIFXXGOKSHPRE-UHFFFAOYSA-N 0.000 description 1
- IUWNQHUQGMVVKY-UHFFFAOYSA-N n-[2-[4-(2-bromoanilino)piperidin-1-yl]-2-oxoethyl]-5-phenyl-1,2-oxazole-3-carboxamide Chemical compound BrC1=CC=CC=C1NC1CCN(C(=O)CNC(=O)C2=NOC(=C2)C=2C=CC=CC=2)CC1 IUWNQHUQGMVVKY-UHFFFAOYSA-N 0.000 description 1
- ZRNIUDKBANEGCD-UHFFFAOYSA-N n-[2-[4-(2-bromophenoxy)piperidin-1-yl]-2-oxoethyl]-4-phenylbenzamide Chemical compound BrC1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)CC1 ZRNIUDKBANEGCD-UHFFFAOYSA-N 0.000 description 1
- TXFYHYPFAXPIHX-UHFFFAOYSA-N n-[2-[4-(2-bromophenoxy)piperidin-1-yl]-2-oxoethyl]-5-phenyl-1,2-oxazole-3-carboxamide Chemical compound BrC1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C2=NOC(=C2)C=2C=CC=CC=2)CC1 TXFYHYPFAXPIHX-UHFFFAOYSA-N 0.000 description 1
- GLIZBENIWAFGGG-UHFFFAOYSA-N n-[2-[4-(2-carbamoylphenoxy)piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound NC(=O)C1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 GLIZBENIWAFGGG-UHFFFAOYSA-N 0.000 description 1
- QBFPYWCVYCKOKU-UHFFFAOYSA-N n-[2-[4-(2-chloro-5-fluorophenoxy)piperidin-1-yl]-2-oxoethyl]-1-(3-fluorophenyl)triazole-4-carboxamide Chemical compound FC1=CC=CC(N2N=NC(=C2)C(=O)NCC(=O)N2CCC(CC2)OC=2C(=CC=C(F)C=2)Cl)=C1 QBFPYWCVYCKOKU-UHFFFAOYSA-N 0.000 description 1
- ORDWQRZKGIOLHO-UHFFFAOYSA-N n-[2-[4-(2-chloro-5-fluorophenoxy)piperidin-1-yl]-2-oxoethyl]-1-(3-methylphenyl)triazole-4-carboxamide Chemical compound CC1=CC=CC(N2N=NC(=C2)C(=O)NCC(=O)N2CCC(CC2)OC=2C(=CC=C(F)C=2)Cl)=C1 ORDWQRZKGIOLHO-UHFFFAOYSA-N 0.000 description 1
- XRDRSWAJYJOXKM-UHFFFAOYSA-N n-[2-[4-(2-chloro-5-fluorophenoxy)piperidin-1-yl]-2-oxoethyl]-1-morpholin-4-yltriazole-4-carboxamide Chemical compound FC1=CC=C(Cl)C(OC2CCN(CC2)C(=O)CNC(=O)C=2N=NN(C=2)N2CCOCC2)=C1 XRDRSWAJYJOXKM-UHFFFAOYSA-N 0.000 description 1
- USVNFQZHIZBJTI-UHFFFAOYSA-N n-[2-[4-(2-chloro-5-fluorophenoxy)piperidin-1-yl]-2-oxoethyl]-1-phenylimidazole-4-carboxamide Chemical class FC1=CC=C(Cl)C(OC2CCN(CC2)C(=O)CNC(=O)C=2N=CN(C=2)C=2C=CC=CC=2)=C1 USVNFQZHIZBJTI-UHFFFAOYSA-N 0.000 description 1
- IMNSGCAUWONPEE-UHFFFAOYSA-N n-[2-[4-(2-chloro-5-fluorophenoxy)piperidin-1-yl]-2-oxoethyl]-2-phenyl-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound FC1=CC=C(Cl)C(OC2CCN(CC2)C(=O)CNC(=O)C=2NC=3C=C(SC=3C=2)C=2C=CC=CC=2)=C1 IMNSGCAUWONPEE-UHFFFAOYSA-N 0.000 description 1
- LTCKSRPBZATNQS-UHFFFAOYSA-N n-[2-[4-(2-chloro-5-fluorophenoxy)piperidin-1-yl]-2-oxoethyl]-5-phenylpyridine-2-carboxamide Chemical compound FC1=CC=C(Cl)C(OC2CCN(CC2)C(=O)CNC(=O)C=2N=CC(=CC=2)C=2C=CC=CC=2)=C1 LTCKSRPBZATNQS-UHFFFAOYSA-N 0.000 description 1
- XOEFGDDDWBYUIB-UHFFFAOYSA-N n-[2-[4-(2-chloro-n-methylanilino)piperidin-1-yl]-2-oxoethyl]-4-phenylbenzamide Chemical compound C=1C=CC=C(Cl)C=1N(C)C(CC1)CCN1C(=O)CNC(=O)C(C=C1)=CC=C1C1=CC=CC=C1 XOEFGDDDWBYUIB-UHFFFAOYSA-N 0.000 description 1
- SQZWBIDXRBZMDA-UHFFFAOYSA-N n-[2-[4-(2-chloroanilino)piperidin-1-yl]-2-oxoethyl]-3-(2-fluorophenyl)-1h-pyrazole-5-carboxamide Chemical class FC1=CC=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)NC=2C(=CC=CC=2)Cl)=NN1 SQZWBIDXRBZMDA-UHFFFAOYSA-N 0.000 description 1
- MLTPGILPIPULEM-UHFFFAOYSA-N n-[2-[4-(2-chloroanilino)piperidin-1-yl]-2-oxoethyl]-3-(2-methoxyphenyl)-1h-pyrazole-5-carboxamide Chemical class COC1=CC=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)NC=2C(=CC=CC=2)Cl)=NN1 MLTPGILPIPULEM-UHFFFAOYSA-N 0.000 description 1
- UGGAMMYWHJWTMF-UHFFFAOYSA-N n-[2-[4-(2-chloroanilino)piperidin-1-yl]-2-oxoethyl]-3-(3-fluorophenyl)-1h-pyrazole-5-carboxamide Chemical class FC1=CC=CC(C=2NN=C(C=2)C(=O)NCC(=O)N2CCC(CC2)NC=2C(=CC=CC=2)Cl)=C1 UGGAMMYWHJWTMF-UHFFFAOYSA-N 0.000 description 1
- WFAALKOUHKWGCA-UHFFFAOYSA-N n-[2-[4-(2-chloroanilino)piperidin-1-yl]-2-oxoethyl]-3-(3-hydroxyphenyl)-1h-pyrazole-5-carboxamide Chemical class OC1=CC=CC(C=2NN=C(C=2)C(=O)NCC(=O)N2CCC(CC2)NC=2C(=CC=CC=2)Cl)=C1 WFAALKOUHKWGCA-UHFFFAOYSA-N 0.000 description 1
- OKWAREZJEGHQRD-UHFFFAOYSA-N n-[2-[4-(2-chloroanilino)piperidin-1-yl]-2-oxoethyl]-3-[2-(trifluoromethyl)phenyl]-1h-pyrazole-5-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)NC=2C(=CC=CC=2)Cl)=NN1 OKWAREZJEGHQRD-UHFFFAOYSA-N 0.000 description 1
- UEMGNPVRLDFYRX-UHFFFAOYSA-N n-[2-[4-(2-chloroanilino)piperidin-1-yl]-2-oxoethyl]-4-phenylbenzamide Chemical compound ClC1=CC=CC=C1NC1CCN(C(=O)CNC(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)CC1 UEMGNPVRLDFYRX-UHFFFAOYSA-N 0.000 description 1
- PDYMYJMEFKSSOL-UHFFFAOYSA-N n-[2-[4-(2-chloroanilino)piperidin-1-yl]-2-oxoethyl]-5-(2-fluorophenyl)-1,2-oxazole-3-carboxamide Chemical class FC1=CC=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)NC=2C(=CC=CC=2)Cl)=NO1 PDYMYJMEFKSSOL-UHFFFAOYSA-N 0.000 description 1
- QFLWLFPNIDECHE-UHFFFAOYSA-N n-[2-[4-(2-chlorophenoxy)piperidin-1-yl]-2-oxoethyl]-1-(3,5-difluorophenyl)triazole-4-carboxamide Chemical compound FC1=CC(F)=CC(N2N=NC(=C2)C(=O)NCC(=O)N2CCC(CC2)OC=2C(=CC=CC=2)Cl)=C1 QFLWLFPNIDECHE-UHFFFAOYSA-N 0.000 description 1
- CQUZVJRUQZWSJI-UHFFFAOYSA-N n-[2-[4-(2-chlorophenoxy)piperidin-1-yl]-2-oxoethyl]-1-(5-fluoropyridin-3-yl)triazole-4-carboxamide Chemical compound FC1=CN=CC(N2N=NC(=C2)C(=O)NCC(=O)N2CCC(CC2)OC=2C(=CC=CC=2)Cl)=C1 CQUZVJRUQZWSJI-UHFFFAOYSA-N 0.000 description 1
- GNSCZTQFUZQSLY-UHFFFAOYSA-N n-[2-[4-(2-chlorophenoxy)piperidin-1-yl]-2-oxoethyl]-1-phenylpyrazole-4-carboxamide Chemical compound ClC1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C2=CN(N=C2)C=2C=CC=CC=2)CC1 GNSCZTQFUZQSLY-UHFFFAOYSA-N 0.000 description 1
- BVEWAJWEKWUAHX-UHFFFAOYSA-N n-[2-[4-(2-chlorophenoxy)piperidin-1-yl]-2-oxoethyl]-1-pyridin-3-yltriazole-4-carboxamide Chemical compound ClC1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C=2N=NN(C=2)C=2C=NC=CC=2)CC1 BVEWAJWEKWUAHX-UHFFFAOYSA-N 0.000 description 1
- RJUZKNPHBBGMEE-UHFFFAOYSA-N n-[2-[4-(2-chlorophenoxy)piperidin-1-yl]-2-oxoethyl]-3-(2-fluorophenyl)-1h-pyrazole-5-carboxamide Chemical class FC1=CC=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)OC=2C(=CC=CC=2)Cl)=NN1 RJUZKNPHBBGMEE-UHFFFAOYSA-N 0.000 description 1
- HQHOPUBHQIKRMO-UHFFFAOYSA-N n-[2-[4-(2-chlorophenoxy)piperidin-1-yl]-2-oxoethyl]-3-[4-(trifluoromethyl)phenyl]-1h-pyrazole-5-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)OC=2C(=CC=CC=2)Cl)=NN1 HQHOPUBHQIKRMO-UHFFFAOYSA-N 0.000 description 1
- DPCGGNFIMNGFCT-UHFFFAOYSA-N n-[2-[4-(2-chlorophenoxy)piperidin-1-yl]-2-oxoethyl]-3-pyridin-2-yl-1h-pyrazole-5-carboxamide Chemical compound ClC1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2N=CC=CC=2)CC1 DPCGGNFIMNGFCT-UHFFFAOYSA-N 0.000 description 1
- DTTKKZLMJWBKAX-UHFFFAOYSA-N n-[2-[4-(2-chlorophenoxy)piperidin-1-yl]-2-oxoethyl]-3-pyridin-3-yl-1h-pyrazole-5-carboxamide Chemical compound ClC1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=NC=CC=2)CC1 DTTKKZLMJWBKAX-UHFFFAOYSA-N 0.000 description 1
- HVCVBESGIVKFMC-UHFFFAOYSA-N n-[2-[4-(2-chlorophenoxy)piperidin-1-yl]-2-oxoethyl]-4-(1,3,4-oxadiazol-2-yl)benzamide Chemical compound ClC1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C=2C=CC(=CC=2)C=2OC=NN=2)CC1 HVCVBESGIVKFMC-UHFFFAOYSA-N 0.000 description 1
- DDQMKWWBCNFSLB-UHFFFAOYSA-N n-[2-[4-(2-chlorophenoxy)piperidin-1-yl]-2-oxoethyl]-4-(5-methyl-1,3,4-oxadiazol-2-yl)benzamide Chemical compound O1C(C)=NN=C1C1=CC=C(C(=O)NCC(=O)N2CCC(CC2)OC=2C(=CC=CC=2)Cl)C=C1 DDQMKWWBCNFSLB-UHFFFAOYSA-N 0.000 description 1
- NNKXPEJDUYDGBH-UHFFFAOYSA-N n-[2-[4-(2-chlorophenoxy)piperidin-1-yl]-2-oxoethyl]-4-[3-(dimethylamino)phenyl]benzamide Chemical compound CN(C)C1=CC=CC(C=2C=CC(=CC=2)C(=O)NCC(=O)N2CCC(CC2)OC=2C(=CC=CC=2)Cl)=C1 NNKXPEJDUYDGBH-UHFFFAOYSA-N 0.000 description 1
- LVVXQQDLOJHCDK-UHFFFAOYSA-N n-[2-[4-(2-chlorophenoxy)piperidin-1-yl]-2-oxoethyl]-4-phenylpyrazole-1-carboxamide Chemical compound ClC1=CC=CC=C1OC1CCN(C(=O)CNC(=O)N2N=CC(=C2)C=2C=CC=CC=2)CC1 LVVXQQDLOJHCDK-UHFFFAOYSA-N 0.000 description 1
- DWYYKLPXTNBGQC-UHFFFAOYSA-N n-[2-[4-(2-chlorophenoxy)piperidin-1-yl]-2-oxoethyl]-5-phenylpyridine-2-carboxamide Chemical compound ClC1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C=2N=CC(=CC=2)C=2C=CC=CC=2)CC1 DWYYKLPXTNBGQC-UHFFFAOYSA-N 0.000 description 1
- XYTHNDSHRYENOO-UHFFFAOYSA-N n-[2-[4-(2-chlorophenoxy)piperidin-1-yl]-2-oxoethyl]-6-pyrazol-1-ylimidazo[1,2-a]pyridine-2-carboxamide Chemical compound ClC1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C=2N=C3C=CC(=CN3C=2)N2N=CC=C2)CC1 XYTHNDSHRYENOO-UHFFFAOYSA-N 0.000 description 1
- TUULZIHYKXUNBK-UHFFFAOYSA-N n-[2-[4-(2-chlorophenyl)sulfanylpiperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound ClC1=CC=CC=C1SC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 TUULZIHYKXUNBK-UHFFFAOYSA-N 0.000 description 1
- PBAACEKUXMTVQN-UHFFFAOYSA-N n-[2-[4-(2-chloropyridin-3-yl)oxypiperidin-1-yl]-2-oxoethyl]-3-(4-fluorophenyl)-1h-pyrazole-5-carboxamide Chemical compound C1=CC(F)=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)OC=2C(=NC=CC=2)Cl)=NN1 PBAACEKUXMTVQN-UHFFFAOYSA-N 0.000 description 1
- UZDOEXMWGAVVBA-UHFFFAOYSA-N n-[2-[4-(2-chloropyridin-3-yl)oxypiperidin-1-yl]-2-oxoethyl]-5-(4-fluorophenyl)-1,2-oxazole-3-carboxamide Chemical compound C1=CC(F)=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)OC=2C(=NC=CC=2)Cl)=NO1 UZDOEXMWGAVVBA-UHFFFAOYSA-N 0.000 description 1
- PQLJHGORBYLEKR-UHFFFAOYSA-N n-[2-[4-(2-cyanophenoxy)piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound C1CC(OC=2C(=CC=CC=2)C#N)CCN1C(=O)CNC(=O)C(=NN1)C=C1C1=CC=CC=C1 PQLJHGORBYLEKR-UHFFFAOYSA-N 0.000 description 1
- HEZGJUOBJWKWAE-UHFFFAOYSA-N n-[2-[4-(2-formylphenoxy)piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound O=CC1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 HEZGJUOBJWKWAE-UHFFFAOYSA-N 0.000 description 1
- MCTHOEYUMWNULO-UHFFFAOYSA-N n-[2-[4-(2-hydroxyphenoxy)piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound OC1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 MCTHOEYUMWNULO-UHFFFAOYSA-N 0.000 description 1
- JBVNMGBOMGFTEA-UHFFFAOYSA-N n-[2-[4-(2-methylanilino)piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound CC1=CC=CC=C1NC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 JBVNMGBOMGFTEA-UHFFFAOYSA-N 0.000 description 1
- USXJGPACGOUYCA-UHFFFAOYSA-N n-[2-[4-(2-methylpyridin-3-yl)oxypiperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound CC1=NC=CC=C1OC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 USXJGPACGOUYCA-UHFFFAOYSA-N 0.000 description 1
- VWOSFUOLZVTQLH-UHFFFAOYSA-N n-[2-[4-(2-methylsulfonylphenoxy)piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound CS(=O)(=O)C1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 VWOSFUOLZVTQLH-UHFFFAOYSA-N 0.000 description 1
- YWWCWVZZNXCOCN-UHFFFAOYSA-N n-[2-[4-(3-chlorophenoxy)piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound ClC1=CC=CC(OC2CCN(CC2)C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)=C1 YWWCWVZZNXCOCN-UHFFFAOYSA-N 0.000 description 1
- OBYSXHARNGLINB-UHFFFAOYSA-N n-[2-[4-(3-cyanoanilino)piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound C1CC(NC=2C=C(C=CC=2)C#N)CCN1C(=O)CNC(=O)C(=NN1)C=C1C1=CC=CC=C1 OBYSXHARNGLINB-UHFFFAOYSA-N 0.000 description 1
- TYBVKIPMLUSAOJ-UHFFFAOYSA-N n-[2-[4-(3-cyanophenoxy)piperidin-1-yl]-2-oxoethyl]-1-phenyltriazole-4-carboxamide Chemical compound C1CC(OC=2C=C(C=CC=2)C#N)CCN1C(=O)CNC(=O)C(N=N1)=CN1C1=CC=CC=C1 TYBVKIPMLUSAOJ-UHFFFAOYSA-N 0.000 description 1
- ILPIMPZSSUKLSX-UHFFFAOYSA-N n-[2-[4-(3-cyanophenoxy)piperidin-1-yl]-2-oxoethyl]-1-pyridin-3-yltriazole-4-carboxamide Chemical compound C1CC(OC=2C=C(C=CC=2)C#N)CCN1C(=O)CNC(=O)C(N=N1)=CN1C1=CC=CN=C1 ILPIMPZSSUKLSX-UHFFFAOYSA-N 0.000 description 1
- IXIZADTUIXLHKO-UHFFFAOYSA-N n-[2-[4-(3-cyanophenoxy)piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound C1CC(OC=2C=C(C=CC=2)C#N)CCN1C(=O)CNC(=O)C(=NN1)C=C1C1=CC=CC=C1 IXIZADTUIXLHKO-UHFFFAOYSA-N 0.000 description 1
- MKJHYRYUDCPPLE-UHFFFAOYSA-N n-[2-[4-(3-methylphenoxy)piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound CC1=CC=CC(OC2CCN(CC2)C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)=C1 MKJHYRYUDCPPLE-UHFFFAOYSA-N 0.000 description 1
- RTNRLPYMJXGTBZ-UHFFFAOYSA-N n-[2-[4-(4-methylpyridin-3-yl)oxypiperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound CC1=CC=NC=C1OC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 RTNRLPYMJXGTBZ-UHFFFAOYSA-N 0.000 description 1
- FOOPBMPCPXTHPU-UHFFFAOYSA-N n-[2-[4-(5-bromo-2-methoxyanilino)piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical class COC1=CC=C(Br)C=C1NC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 FOOPBMPCPXTHPU-UHFFFAOYSA-N 0.000 description 1
- WSVZKORQNYAZEX-UHFFFAOYSA-N n-[2-[4-(5-chloropyridin-3-yl)oxypiperidin-1-yl]-2-oxoethyl]-1-(3,5-difluorophenyl)triazole-4-carboxamide Chemical compound FC1=CC(F)=CC(N2N=NC(=C2)C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(Cl)C=NC=2)=C1 WSVZKORQNYAZEX-UHFFFAOYSA-N 0.000 description 1
- GPFZYWOEEBRQLW-UHFFFAOYSA-N n-[2-[4-(5-chloropyridin-3-yl)oxypiperidin-1-yl]-2-oxoethyl]-3-(3-fluorophenyl)-1h-pyrazole-5-carboxamide Chemical compound FC1=CC=CC(C=2NN=C(C=2)C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(Cl)C=NC=2)=C1 GPFZYWOEEBRQLW-UHFFFAOYSA-N 0.000 description 1
- GQEVORZFWKDZJE-UHFFFAOYSA-N n-[2-[4-(5-chloropyridin-3-yl)oxypiperidin-1-yl]-2-oxoethyl]-3-(4-fluorophenyl)-1h-pyrazole-5-carboxamide Chemical compound C1=CC(F)=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(Cl)C=NC=2)=NN1 GQEVORZFWKDZJE-UHFFFAOYSA-N 0.000 description 1
- XYMAZIALTDDUIP-UHFFFAOYSA-N n-[2-[4-(5-chloropyridin-3-yl)oxypiperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound ClC1=CN=CC(OC2CCN(CC2)C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)=C1 XYMAZIALTDDUIP-UHFFFAOYSA-N 0.000 description 1
- OZUFJDKDPNPGFR-UHFFFAOYSA-N n-[2-[4-(5-chloropyridin-3-yl)oxypiperidin-1-yl]-2-oxoethyl]-5-(3-fluorophenyl)-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=CC(C=2ON=C(C=2)C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(Cl)C=NC=2)=C1 OZUFJDKDPNPGFR-UHFFFAOYSA-N 0.000 description 1
- UIDKAUBYKQKRML-UHFFFAOYSA-N n-[2-[4-(5-chloropyridin-3-yl)oxypiperidin-1-yl]-2-oxoethyl]-5-(4-fluorophenyl)-1,2-oxazole-3-carboxamide Chemical compound C1=CC(F)=CC=C1C1=CC(C(=O)NCC(=O)N2CCC(CC2)OC=2C=C(Cl)C=NC=2)=NO1 UIDKAUBYKQKRML-UHFFFAOYSA-N 0.000 description 1
- VMHLFJLZGRBKBE-UHFFFAOYSA-N n-[2-[4-(5-cyano-2-methylanilino)piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical class CC1=CC=C(C#N)C=C1NC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 VMHLFJLZGRBKBE-UHFFFAOYSA-N 0.000 description 1
- PWZBIOCDMGTCHT-UHFFFAOYSA-N n-[2-[4-(5-cyano-2-methylphenoxy)piperidin-1-yl]-2-oxoethyl]-1-phenylimidazole-4-carboxamide Chemical class CC1=CC=C(C#N)C=C1OC1CCN(C(=O)CNC(=O)C=2N=CN(C=2)C=2C=CC=CC=2)CC1 PWZBIOCDMGTCHT-UHFFFAOYSA-N 0.000 description 1
- YIXKOEGIWVLRFG-UHFFFAOYSA-N n-[2-[4-(6-chloropyridin-2-yl)oxypiperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound ClC1=CC=CC(OC2CCN(CC2)C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)=N1 YIXKOEGIWVLRFG-UHFFFAOYSA-N 0.000 description 1
- ODVMMVWKYBXLCA-UHFFFAOYSA-N n-[2-[4-[2-(hydroxyiminomethyl)phenoxy]piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical class ON=CC1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 ODVMMVWKYBXLCA-UHFFFAOYSA-N 0.000 description 1
- LSYYCELXJDBZQA-UHFFFAOYSA-N n-[2-[4-[2-(hydroxymethyl)phenoxy]piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound OCC1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 LSYYCELXJDBZQA-UHFFFAOYSA-N 0.000 description 1
- WVNYGZREPZQXRL-UHFFFAOYSA-N n-[2-[4-[2-(methoxyiminomethyl)phenoxy]piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical class CON=CC1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 WVNYGZREPZQXRL-UHFFFAOYSA-N 0.000 description 1
- AJRDIDUELMZYPP-UHFFFAOYSA-N n-[2-[4-[2-(methylcarbamoyl)phenoxy]piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound CNC(=O)C1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 AJRDIDUELMZYPP-UHFFFAOYSA-N 0.000 description 1
- LSJZRMCMNDWHHN-UHFFFAOYSA-N n-[2-[4-[2-fluoro-5-(trifluoromethyl)phenoxy]piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound FC1=CC=C(C(F)(F)F)C=C1OC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 LSJZRMCMNDWHHN-UHFFFAOYSA-N 0.000 description 1
- IPBHKJTZNMADGD-UHFFFAOYSA-N n-[2-[4-[3-fluoro-5-(trifluoromethyl)phenoxy]piperidin-1-yl]-2-oxoethyl]-1-phenylimidazole-4-carboxamide Chemical compound FC(F)(F)C1=CC(F)=CC(OC2CCN(CC2)C(=O)CNC(=O)C=2N=CN(C=2)C=2C=CC=CC=2)=C1 IPBHKJTZNMADGD-UHFFFAOYSA-N 0.000 description 1
- FTTKXUQKKQIOCX-UHFFFAOYSA-N n-[2-[4-[3-fluoro-5-(trifluoromethyl)phenoxy]piperidin-1-yl]-2-oxoethyl]-1-pyridin-3-yltriazole-4-carboxamide Chemical compound FC(F)(F)C1=CC(F)=CC(OC2CCN(CC2)C(=O)CNC(=O)C=2N=NN(C=2)C=2C=NC=CC=2)=C1 FTTKXUQKKQIOCX-UHFFFAOYSA-N 0.000 description 1
- JLPNPPMXNYGUQE-UHFFFAOYSA-N n-[2-[4-[3-fluoro-5-(trifluoromethyl)phenoxy]piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound FC(F)(F)C1=CC(F)=CC(OC2CCN(CC2)C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)=C1 JLPNPPMXNYGUQE-UHFFFAOYSA-N 0.000 description 1
- XXZFYGVUMOUZCB-UHFFFAOYSA-N n-[2-[4-[4-fluoro-2-(trifluoromethyl)anilino]piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound FC(F)(F)C1=CC(F)=CC=C1NC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 XXZFYGVUMOUZCB-UHFFFAOYSA-N 0.000 description 1
- SHFMSQWRLSJMEJ-UHFFFAOYSA-N n-[2-[4-[4-fluoro-3-(trifluoromethyl)phenoxy]piperidin-1-yl]-2-oxoethyl]-1-phenylimidazole-4-carboxamide Chemical compound C1=C(C(F)(F)F)C(F)=CC=C1OC1CCN(C(=O)CNC(=O)C=2N=CN(C=2)C=2C=CC=CC=2)CC1 SHFMSQWRLSJMEJ-UHFFFAOYSA-N 0.000 description 1
- TXMRQPFHFMWFFL-UHFFFAOYSA-N n-[2-[4-[4-fluoro-3-(trifluoromethyl)phenoxy]piperidin-1-yl]-2-oxoethyl]-1-pyridin-3-yltriazole-4-carboxamide Chemical compound C1=C(C(F)(F)F)C(F)=CC=C1OC1CCN(C(=O)CNC(=O)C=2N=NN(C=2)C=2C=NC=CC=2)CC1 TXMRQPFHFMWFFL-UHFFFAOYSA-N 0.000 description 1
- KDKCBLLPSZWXRN-UHFFFAOYSA-N n-[2-[4-[4-fluoro-3-(trifluoromethyl)phenoxy]piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound C1=C(C(F)(F)F)C(F)=CC=C1OC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 KDKCBLLPSZWXRN-UHFFFAOYSA-N 0.000 description 1
- FCMPOSVCDYMBBY-UHFFFAOYSA-N n-[2-[4-[5-fluoro-2-(trifluoromethyl)anilino]piperidin-1-yl]-2-oxoethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound FC1=CC=C(C(F)(F)F)C(NC2CCN(CC2)C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)=C1 FCMPOSVCDYMBBY-UHFFFAOYSA-N 0.000 description 1
- NXLHLAPPWKQPGM-UHFFFAOYSA-N n-[2-[4-[n-methyl-2-(trifluoromethyl)anilino]piperidin-1-yl]-2-oxoethyl]-5-phenyl-1,2-oxazole-3-carboxamide Chemical class C=1C=CC=C(C(F)(F)F)C=1N(C)C(CC1)CCN1C(=O)CNC(=O)C(=NO1)C=C1C1=CC=CC=C1 NXLHLAPPWKQPGM-UHFFFAOYSA-N 0.000 description 1
- ANDHQVNXXBGCBQ-UHFFFAOYSA-N n-[2-oxo-2-(4-pyridin-4-yloxypiperidin-1-yl)ethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound C1CC(OC=2C=CN=CC=2)CCN1C(=O)CNC(=O)C(=NN1)C=C1C1=CC=CC=C1 ANDHQVNXXBGCBQ-UHFFFAOYSA-N 0.000 description 1
- VLCOLUDPRTXPBE-UHFFFAOYSA-N n-[2-oxo-2-[3-[3-(trifluoromethyl)phenoxy]azetidin-1-yl]ethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound FC(F)(F)C1=CC=CC(OC2CN(C2)C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)=C1 VLCOLUDPRTXPBE-UHFFFAOYSA-N 0.000 description 1
- XRMNPYZNSRUEEW-UHFFFAOYSA-N n-[2-oxo-2-[3-[3-(trifluoromethyl)phenoxy]azetidin-1-yl]ethyl]-3-pyridin-3-yl-1h-pyrazole-5-carboxamide Chemical class FC(F)(F)C1=CC=CC(OC2CN(C2)C(=O)CNC(=O)C2=NNC(=C2)C=2C=NC=CC=2)=C1 XRMNPYZNSRUEEW-UHFFFAOYSA-N 0.000 description 1
- FQDYDIAATBPSFP-UHFFFAOYSA-N n-[2-oxo-2-[3-[3-(trifluoromethyl)phenoxy]pyrrolidin-1-yl]ethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound FC(F)(F)C1=CC=CC(OC2CN(CC2)C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)=C1 FQDYDIAATBPSFP-UHFFFAOYSA-N 0.000 description 1
- YWHMCRIKEXLLFC-UHFFFAOYSA-N n-[2-oxo-2-[4-(3,4,5-trifluorophenoxy)piperidin-1-yl]ethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical class FC1=C(F)C(F)=CC(OC2CCN(CC2)C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)=C1 YWHMCRIKEXLLFC-UHFFFAOYSA-N 0.000 description 1
- XJJQRNRRAFNMCA-UHFFFAOYSA-N n-[2-oxo-2-[4-[2-(trifluoromethyl)anilino]piperidin-1-yl]ethyl]-4-phenylbenzamide Chemical compound FC(F)(F)C1=CC=CC=C1NC1CCN(C(=O)CNC(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)CC1 XJJQRNRRAFNMCA-UHFFFAOYSA-N 0.000 description 1
- XGNRCTMTNDXSTQ-UHFFFAOYSA-N n-[2-oxo-2-[4-[2-(trifluoromethyl)anilino]piperidin-1-yl]ethyl]-5-phenyl-1,2-oxazole-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1NC1CCN(C(=O)CNC(=O)C2=NOC(=C2)C=2C=CC=CC=2)CC1 XGNRCTMTNDXSTQ-UHFFFAOYSA-N 0.000 description 1
- VQLNWFGZQRNYBR-UHFFFAOYSA-N n-[2-oxo-2-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-1-pyridin-3-yltriazole-4-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C=2N=NN(C=2)C=2C=NC=CC=2)CC1 VQLNWFGZQRNYBR-UHFFFAOYSA-N 0.000 description 1
- LJHTVSGWFAXWGQ-UHFFFAOYSA-N n-[2-oxo-2-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 LJHTVSGWFAXWGQ-UHFFFAOYSA-N 0.000 description 1
- NCKQFZBBVWTDSR-UHFFFAOYSA-N n-[2-oxo-2-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-4-phenylbenzamide Chemical compound FC(F)(F)C1=CC=CC=C1OC1CCN(C(=O)CNC(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)CC1 NCKQFZBBVWTDSR-UHFFFAOYSA-N 0.000 description 1
- LZSCCHXODFWMOE-UHFFFAOYSA-N n-[2-oxo-2-[4-[2-(trifluoromethyl)phenyl]sulfanylpiperidin-1-yl]ethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1SC1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 LZSCCHXODFWMOE-UHFFFAOYSA-N 0.000 description 1
- ULMNTNWMGLKHOJ-UHFFFAOYSA-N n-[2-oxo-2-[4-[2-(trifluoromethyl)phenyl]sulfinylpiperidin-1-yl]ethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1S(=O)C1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 ULMNTNWMGLKHOJ-UHFFFAOYSA-N 0.000 description 1
- JKJXJIPPQUHJIW-UHFFFAOYSA-N n-[2-oxo-2-[4-[2-(trifluoromethyl)phenyl]sulfonylpiperidin-1-yl]ethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1S(=O)(=O)C1CCN(C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)CC1 JKJXJIPPQUHJIW-UHFFFAOYSA-N 0.000 description 1
- LKNIYPRCTXLXQH-UHFFFAOYSA-N n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-1-phenylimidazole-4-carboxamide Chemical compound FC(F)(F)C1=CC=CC(OC2CCN(CC2)C(=O)CNC(=O)C=2N=CN(C=2)C=2C=CC=CC=2)=C1 LKNIYPRCTXLXQH-UHFFFAOYSA-N 0.000 description 1
- BTACWTRLUFGORP-UHFFFAOYSA-N n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-3-[2-(trifluoromethyl)phenyl]-1h-pyrazole-5-carboxamide Chemical compound FC(F)(F)C1=CC=CC(OC2CCN(CC2)C(=O)CNC(=O)C2=NNC(=C2)C=2C(=CC=CC=2)C(F)(F)F)=C1 BTACWTRLUFGORP-UHFFFAOYSA-N 0.000 description 1
- OGKDYSLUPAVJGG-UHFFFAOYSA-N n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-3-pyridin-3-yl-1h-pyrazole-5-carboxamide Chemical class FC(F)(F)C1=CC=CC(OC2CCN(CC2)C(=O)CNC(=O)C2=NNC(=C2)C=2C=NC=CC=2)=C1 OGKDYSLUPAVJGG-UHFFFAOYSA-N 0.000 description 1
- LKWPGLCZVNYLPL-UHFFFAOYSA-N n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-4-(pyrrolidine-1-carbonyl)benzamide Chemical class FC(F)(F)C1=CC=CC(OC2CCN(CC2)C(=O)CNC(=O)C=2C=CC(=CC=2)C(=O)N2CCCC2)=C1 LKWPGLCZVNYLPL-UHFFFAOYSA-N 0.000 description 1
- YGRXEJSOMVCUOF-UHFFFAOYSA-N n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-5-phenyl-1,2-oxazole-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(OC2CCN(CC2)C(=O)CNC(=O)C2=NOC(=C2)C=2C=CC=CC=2)=C1 YGRXEJSOMVCUOF-UHFFFAOYSA-N 0.000 description 1
- AGQAEHIUHXDMEI-UHFFFAOYSA-N n-[2-oxo-2-[4-[3-(trifluoromethyl)phenoxy]piperidin-1-yl]ethyl]-9h-carbazole-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(OC2CCN(CC2)C(=O)CNC(=O)C=2C=C3C4=CC=CC=C4NC3=CC=2)=C1 AGQAEHIUHXDMEI-UHFFFAOYSA-N 0.000 description 1
- QCJACBAPSVJZGI-UHFFFAOYSA-N n-[2-oxo-2-[4-[5-(trifluoromethyl)pyridin-3-yl]oxypiperidin-1-yl]ethyl]-3-phenyl-1h-pyrazole-5-carboxamide Chemical class FC(F)(F)C1=CN=CC(OC2CCN(CC2)C(=O)CNC(=O)C2=NNC(=C2)C=2C=CC=CC=2)=C1 QCJACBAPSVJZGI-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- XDUHQPOXLUAVEE-BPMMELMSSA-N oleoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCC\C=C/CCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 XDUHQPOXLUAVEE-BPMMELMSSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- QBYOCCWNZAOZTL-MDMKAECGSA-N palmitoleoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCC\C=C/CCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 QBYOCCWNZAOZTL-MDMKAECGSA-N 0.000 description 1
- MNBKLUUYKPBKDU-BBECNAHFSA-N palmitoyl-CoA Chemical group O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MNBKLUUYKPBKDU-BBECNAHFSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- SIARJEKBADXQJG-LFZQUHGESA-N stearoyl-CoA Chemical group O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SIARJEKBADXQJG-LFZQUHGESA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000004952 trihaloalkoxy group Chemical group 0.000 description 1
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443066P | 2017-01-06 | 2017-01-06 | |
| US62/443,066 | 2017-01-06 | ||
| PCT/US2018/012697 WO2018129403A1 (en) | 2017-01-06 | 2018-01-05 | Methods for the treatment of neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20190108118A true KR20190108118A (ko) | 2019-09-23 |
Family
ID=62782012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197022664A Ceased KR20190108118A (ko) | 2017-01-06 | 2018-01-05 | 신경계 장애의 치료를 위한 방법 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10973810B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3566055B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2020514293A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20190108118A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110392833A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018205275B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019013954A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3049010A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201991650A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3025460T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL304017A (cg-RX-API-DMAC7.html) |
| MA (1) | MA47212A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019008124A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018129403A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3529245A4 (en) | 2016-10-24 | 2020-12-23 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THE LATEST |
| MA47212A (fr) | 2017-01-06 | 2019-11-13 | Yumanity Therapeutics Inc | Méthodes de traitement de troubles neurologiques |
| WO2019084157A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES THEREOF |
| ES3043183T3 (en) | 2018-03-23 | 2025-11-25 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| MA54829A (fr) | 2019-01-24 | 2021-12-01 | Yumanity Therapeutics Inc | Composés et leurs utilisations |
| US20230078764A1 (en) * | 2019-03-22 | 2023-03-16 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| AU2021217225A1 (en) * | 2020-02-07 | 2022-10-06 | University Of South Florida | Inhibition of beta-arrestin oligomerization in tauopathy |
| WO2022104011A1 (en) * | 2020-11-12 | 2022-05-19 | Yumanity Therapeutics, Inc. | Methods for the treatment of neurological disorders |
| MA71666A (fr) * | 2021-03-18 | 2025-05-30 | Alnylam Pharmaceuticals, Inc. | Compositions d'agent d'arni de stéaroyl-coa désaturase 5 (scd5) et procédés d'utilisation associés |
| CN115607547A (zh) * | 2021-07-14 | 2023-01-17 | 厦门大学 | 一种睑板腺功能障碍动物模型的造模药物、构建方法与应用 |
| EP4674416A1 (en) * | 2023-02-28 | 2026-01-07 | Nagasaki University | Protein aggregate decomposition promoting composition and pharmaceutical composition for prevention or treatment of neurodegenerative diseases associated with protein aggregate formation |
Family Cites Families (285)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4782071A (en) | 1986-11-03 | 1988-11-01 | Warner-Lambert Company | Tetrasubstituted urea cholinergic agents |
| SK282252B6 (sk) | 1995-01-11 | 2001-12-03 | Samjin Pharmaceutical Co., Ltd. | Piperazínové deriváty a farmaceutický prostriedok s ich obsahom |
| TW360653B (en) | 1995-03-01 | 1999-06-11 | Janssen Pharmaceutica Nv | A oxadiazole compound having colon motility stimulating properties, its preparation process and its pharmaceutical composition |
| EP1100511A2 (en) | 1998-06-08 | 2001-05-23 | Sambasiva R. Chavali | Inhibition of delta-9-desaturase activity by saponins |
| US6107313A (en) | 1998-10-02 | 2000-08-22 | Combichem, Inc. | Dopamine receptor antagonists |
| US20040226056A1 (en) * | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
| US20070087363A1 (en) | 1998-12-22 | 2007-04-19 | Myriad Genetics, Incorporated | Therapeutic methods, compounds and compositions |
| EP1193255A4 (en) | 1999-07-01 | 2002-08-07 | Ajinomoto Kk | HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS IN MEDICINE |
| CA2374995C (en) | 1999-07-20 | 2010-12-07 | Dow Agrosciences Llc | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
| CA2376275A1 (en) | 1999-08-20 | 2001-03-01 | Michael John Ricks | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
| EP1315831B8 (en) | 2000-02-24 | 2010-09-01 | Xenon Pharmaceuticals Inc. | Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents |
| WO2001096308A1 (en) | 2000-06-12 | 2001-12-20 | Eisai Co., Ltd. | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
| AU2001264376A1 (en) | 2000-06-15 | 2001-12-24 | Chaconne Nsi Co., Ltd. | Urea derivative useful as an anti-cancer agent and process for preparing same |
| EP1322767B1 (en) | 2000-09-26 | 2008-07-23 | Xenon Pharmaceuticals Inc. | Methods and compositions employing a stearoyl-coa desaturase-hscd5 |
| WO2002040666A2 (en) | 2000-11-17 | 2002-05-23 | Xenon Genetics Inc. | Fat regulated genes, uses thereof, and compounds for modulating same |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7045290B2 (en) | 2001-02-15 | 2006-05-16 | The University Of Chicago | Yeast screens for treatment of human disease |
| US7271181B2 (en) | 2001-05-11 | 2007-09-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| US20050256068A1 (en) | 2001-05-18 | 2005-11-17 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA) |
| US20050043256A1 (en) | 2001-07-30 | 2005-02-24 | Isis Pharmaceuticals, Inc. | Antisense modulation of stearoyl-CoA desaturase expression |
| US6727247B2 (en) | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
| EP1499628A4 (en) | 2002-02-20 | 2005-06-15 | Sirna Therapeutics Inc | RNA-Interferent-mediated inhibition of expression of the steroaryl-COA-desaturase (SCD) gene using SINA (Short Interfering Nucleic Acid) |
| US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| US7105505B2 (en) | 2002-04-18 | 2006-09-12 | Schering Corporation | Benzimidazole derivatives useful as histamine H3 antagonists |
| AU2003264018A1 (en) | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| MXPA05001603A (es) | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Derivados monociclicos como inhibidores de metaloproteinasa de matriz. |
| JP2006516250A (ja) | 2002-12-18 | 2006-06-29 | サイトビア インコーポレイティッド | カスパーゼ活性化剤およびアポトーシス誘導物質としての3,5−二置換−[1,2,4]−オキサジアゾールおよびそれらの誘導体ならびにそれらの使用 |
| EP1635800A2 (en) | 2003-06-10 | 2006-03-22 | Kalypsys, Inc. | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease |
| WO2005011654A2 (en) | 2003-07-29 | 2005-02-10 | Xenon Pharmaceuticals Inc. | Pyridyl derivatives and their use as therapeutic agents |
| US7754711B2 (en) | 2003-07-30 | 2010-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| ES2397389T3 (es) | 2003-07-30 | 2013-03-06 | Xenon Pharmaceuticals Inc. | Derivados de piridilo y su uso como agentes terapéuticos |
| KR20060037410A (ko) | 2003-07-30 | 2006-05-03 | 제논 파마슈티칼스 인크. | 피리다진 유도체 및 그의 치료제로서의 용도 |
| EP2316827B1 (en) | 2003-07-30 | 2016-01-27 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
| KR20060037409A (ko) | 2003-07-30 | 2006-05-03 | 제논 파마슈티칼스 인크. | 피페라진 유도체 및 그의 치료제로서의 용도 |
| US7759348B2 (en) | 2003-07-30 | 2010-07-20 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| MXPA06001480A (es) | 2003-08-06 | 2006-05-15 | Pfizer Prod Inc | Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos. |
| US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| US20060216292A1 (en) | 2003-09-05 | 2006-09-28 | Cellzome Ag | Treatment of neurodegenerative diseases |
| US7973169B2 (en) | 2003-09-06 | 2011-07-05 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| CA2544502A1 (en) | 2003-11-25 | 2005-06-09 | Wisconsin Alumni Research Foundation | Vitamin d analogs for obesity prevention and treatment |
| US7452670B2 (en) | 2003-12-04 | 2008-11-18 | University Of Washington | Methods of identifying agents that diminish cellular toxicity associated with an α-synuclein polypeptide of Parkinson's disease in yeast |
| US8207147B2 (en) | 2003-12-24 | 2012-06-26 | Prosidion Limited | Heterocyclic derivatives as GPCR receptor agonists |
| JP2005213233A (ja) | 2004-02-02 | 2005-08-11 | Fuji Oil Co Ltd | 肝臓ステアロイル‐CoA不飽和化酵素1合成抑制剤 |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| EP1758991B1 (en) | 2004-06-25 | 2013-01-16 | E.I. Du Pont De Nemours And Company | Delta-8 desaturase and its use in making polyunsaturated fatty acids |
| BRPI0418939A (pt) | 2004-07-06 | 2008-04-08 | Xenon Pharmaceuticals Inc | derivados de nicotinamida e sua utilização como agentes terapêuticos |
| ES2325836T3 (es) | 2004-07-26 | 2009-09-21 | Merck Serono Sa | Derivados de la n.hidroxiamida y uso de los mismos. |
| DK1778837T3 (da) | 2004-08-09 | 2008-08-04 | Cellzome Ag | Behandling af neurodegenerative sygdomme ved anvendelse af SCD4-inhibitorer |
| WO2006022442A1 (ja) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| CA2580856A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| CN101083986A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 双环杂环衍生物及其作为硬脂酰CoA去饱和酶(SCD)抑制剂的用途 |
| EP1799667B1 (en) | 2004-09-20 | 2013-03-20 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
| US7951805B2 (en) | 2004-09-20 | 2011-05-31 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
| JP4958787B2 (ja) | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトステアロイル−CoAデサチュラーゼを阻害するためのピリジン誘導体 |
| EP2289510A1 (en) | 2004-09-20 | 2011-03-02 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
| US7767677B2 (en) | 2004-09-20 | 2010-08-03 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| EP2316458A1 (en) | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
| SG161261A1 (en) | 2004-11-10 | 2010-05-27 | Incyte Corp | Lactam compounds and their use as pharmaceuticals |
| CA2588412A1 (en) | 2004-11-22 | 2006-06-01 | Wisconsin Alumni Research Foundation | 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses |
| US20060167044A1 (en) | 2004-12-20 | 2006-07-27 | Arnaiz Damian O | Piperidine derivatives and their use as anti-inflammatory agents |
| KR20070091038A (ko) | 2004-12-24 | 2007-09-06 | 프로시디온 리미티드 | G-단백질 결합 수용체(gpr116) 효능제 및 비만 및당뇨병을 치료하기 위한 이의 용도 |
| BRPI0517423A (pt) | 2004-12-27 | 2008-10-07 | Astrazeneca Ab | composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto |
| WO2006074025A1 (en) | 2004-12-30 | 2006-07-13 | Janssen Pharmaceutica N.V. | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase |
| ATE472327T1 (de) | 2005-01-07 | 2010-07-15 | Hoffmann La Roche | Ä4-(heteroaryl)piperazin-1-ylü-(2,5-substituier e phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen |
| GT200600046A (es) | 2005-02-09 | 2006-09-25 | Terapia de combinacion | |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| WO2006125179A1 (en) | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Tricyclic compounds and their uses as therapeutic agents |
| WO2006125181A2 (en) | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their use as stearoyl-coa desaturase modulators |
| WO2007044085A2 (en) | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
| WO2006125194A2 (en) | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their uses as therapeutic agents |
| WO2007046868A2 (en) | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Thiazolidine derivatives and their uses as therapeutic agents |
| EP2029138A1 (en) | 2005-06-03 | 2009-03-04 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| EP1902051A1 (en) | 2005-06-09 | 2008-03-26 | Merck Frosst Canada Ltd. | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| JPWO2006137465A1 (ja) | 2005-06-24 | 2009-01-22 | 塩野義製薬株式会社 | 含窒素複素環誘導体 |
| WO2007009236A1 (en) | 2005-07-20 | 2007-01-25 | Merck Frosst Canada Ltd. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| AU2006315025A1 (en) | 2005-11-15 | 2007-05-24 | Merck Frosst Canada Ltd. | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2007076055A2 (en) | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| MX2008008529A (es) | 2005-12-29 | 2008-09-26 | Organon Nv | Inhibidores de amida hidrolasa de acido graso. |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| WO2007136746A2 (en) | 2006-05-19 | 2007-11-29 | Xenon Pharmaceuticals Inc. | Macrocyclic compounds and their uses as stearoyl-coa desaturase |
| EP2027121A1 (en) | 2006-05-22 | 2009-02-25 | Merck Frosst Canada Ltd. | Cyclic amine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| DE602007010287D1 (de) | 2006-06-05 | 2010-12-16 | Novartis Ag | Organische verbindungen |
| WO2007143823A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| US7754745B2 (en) | 2006-06-13 | 2010-07-13 | Merck Frosst Canada Ltd. | Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| WO2008003753A1 (en) | 2006-07-07 | 2008-01-10 | Biovitrum Ab (Publ) | Pyrazolo [1,5-a] pyrimidine analogs for use as inhibitors of stearoyl-coa desaturase (scd) activity |
| WO2008008852A2 (en) | 2006-07-11 | 2008-01-17 | Emory University | Cxcr4 antagonists including heteroatoms for the treatment of medical disorders |
| US8080659B2 (en) | 2006-07-11 | 2011-12-20 | Emory University | CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| AU2007283401A1 (en) | 2006-08-09 | 2008-02-14 | Merck Frosst Canada Ltd. | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
| PE20110371A1 (es) | 2006-08-15 | 2011-06-24 | Novartis Ag | COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA |
| WO2008024139A2 (en) | 2006-08-18 | 2008-02-28 | N.V. Organon | Inhibitors of fatty acid amide hydrolase |
| JPWO2008023720A1 (ja) | 2006-08-23 | 2010-01-14 | アステラス製薬株式会社 | ウレア化合物又はその塩 |
| BRPI0719122A2 (pt) | 2006-08-24 | 2013-12-10 | Novartis Ag | Compostos orgânicos |
| WO2008029266A1 (en) | 2006-09-08 | 2008-03-13 | Glenmark Pharmaceuticals S.A. | Stearoyl coa desaturase inhibitors |
| MX2009003080A (es) | 2006-09-22 | 2009-04-02 | Novartis Ag | Compuestos organicos heterociclicos. |
| US7893066B2 (en) | 2006-10-05 | 2011-02-22 | Gilead Palo Alto, Inc. | Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors |
| RU2009112397A (ru) | 2006-10-05 | 2010-10-10 | Си Ви ТЕРАПЬЮТИКС, ИНК (US) | Бициклические азотсодержащие гетероциклические соединения для применения в качестве ингибиторов стеароил соа десатуразы |
| US20090325956A1 (en) | 2006-10-13 | 2009-12-31 | Takahiko Taniguchi | Aromatic amine derivative and use thereof |
| GEP20125425B (en) | 2006-10-18 | 2012-03-26 | Pfizer Prod Inc | Biaryl ether urea compounds |
| US20100004245A1 (en) | 2006-10-20 | 2010-01-07 | Merck Frosst Canada Ltd. | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2008057280A1 (en) | 2006-10-27 | 2008-05-15 | Amgen Inc. | Multi-cyclic compounds and methods of use |
| WO2008056687A1 (en) | 2006-11-09 | 2008-05-15 | Daiichi Sankyo Company, Limited | Novel spiropiperidine derivative |
| JP2010510201A (ja) | 2006-11-20 | 2010-04-02 | グレンマーク・ファーマシューティカルズ・エスエー | ステアリン酸CoA脱飽和酵素阻害剤としてのアセチレン誘導体 |
| SG173409A1 (en) | 2006-11-24 | 2011-08-29 | Ac Immune Sa | N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers |
| CN101589039B (zh) | 2006-12-01 | 2012-09-05 | 默克弗罗斯特加拿大有限公司 | 作为硬脂酰辅酶a △-9去饱和酶抑制剂的氮杂环烷衍生物 |
| TW200826936A (en) * | 2006-12-01 | 2008-07-01 | Merck Frosst Canada Ltd | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| RU2009127095A (ru) | 2006-12-15 | 2011-01-20 | Эбботт Лэборетриз (Us) | Новые оксадиазольные соединения |
| AU2007336238A1 (en) | 2006-12-20 | 2008-06-26 | Novartis Ag | 2-substituted 5-membered heterocycles as SCD inhibitors |
| GB0625604D0 (en) * | 2006-12-21 | 2007-01-31 | Smithkline Beecham Corp | Compounds |
| GB0625605D0 (en) | 2006-12-21 | 2007-01-31 | Smithkline Beecham Corp | Compounds |
| GB0625594D0 (en) | 2006-12-21 | 2007-01-31 | Smithkline Beecham Corp | Compounds |
| GB0625654D0 (en) | 2006-12-21 | 2007-01-31 | Smithkline Beecham Corp | Compounds |
| US20100210649A1 (en) | 2006-12-21 | 2010-08-19 | Sloan-Kettering Institute For Cancer Research | Pyridazinones and furan-containing compounds |
| AR064965A1 (es) | 2007-01-26 | 2009-05-06 | Merck Frosst Canada Inc | Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa |
| WO2008096746A1 (ja) | 2007-02-06 | 2008-08-14 | Takeda Pharmaceutical Company Limited | スピロ化合物およびその用途 |
| EP2125799A1 (en) | 2007-02-28 | 2009-12-02 | Smithkline Beecham Corporation | Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase |
| US20080255153A1 (en) * | 2007-03-28 | 2008-10-16 | Biovitrum Ab (Publ) | New compounds |
| WO2008120759A1 (ja) | 2007-03-30 | 2008-10-09 | Japan Tobacco Inc. | ウレア化合物およびその用途 |
| WO2008120744A1 (ja) | 2007-03-30 | 2008-10-09 | Japan Tobacco Inc. | 5員環アミド化合物およびその用途 |
| WO2008123469A1 (ja) | 2007-03-30 | 2008-10-16 | Japan Tobacco Inc. | 6員環アミド化合物およびその用途 |
| US7662819B2 (en) | 2007-04-09 | 2010-02-16 | Gilead Palo Alto, Inc. | Pteridinone derivatives for use as stearoyl CoA desaturase inhibitors |
| US20080255161A1 (en) | 2007-04-11 | 2008-10-16 | Dmitry Koltun | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| AU2008241313A1 (en) | 2007-04-20 | 2008-10-30 | Merck Frosst Canada Ltd. | Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2008139845A1 (ja) | 2007-04-24 | 2008-11-20 | Daiichi Sankyo Company, Limited | 新規アミド誘導体 |
| AU2008253512A1 (en) | 2007-05-23 | 2008-11-27 | Merck Frosst Canada Ltd. | Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
| US7842696B2 (en) | 2007-06-21 | 2010-11-30 | Forest Laboratories Holdings Limited | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase |
| JP2009019013A (ja) | 2007-07-12 | 2009-01-29 | Daiichi Sankyo Co Ltd | 新規ヘテロアリールピペリジン誘導体 |
| GB0714129D0 (en) | 2007-07-19 | 2007-08-29 | Smithkline Beecham Corp | compounds |
| WO2009012573A1 (en) | 2007-07-20 | 2009-01-29 | Merck Frosst Canada Ltd. | Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| GB0715055D0 (en) | 2007-08-02 | 2007-09-12 | Smithkline Beecham Corp | Compounds |
| CN101821234B (zh) | 2007-08-08 | 2014-06-25 | 格里斯威医药有限责任公司 | 苯氧基吡咯烷衍生物及其应用和组合物 |
| CA2695251C (en) | 2007-08-14 | 2016-06-21 | Bayer Schering Pharma Aktiengesellschaft | Fused imidazoles for cancer treatment |
| WO2009037542A2 (en) | 2007-09-20 | 2009-03-26 | Glenmark Pharmaceuticals, S.A. | Spirocyclic compounds as stearoyl coa desaturase inhibitors |
| ES2499018T3 (es) | 2007-09-20 | 2014-09-26 | Irm Llc | Compuestos y composiciones como moduladores de la actividad de GPR119 |
| GB0721419D0 (en) | 2007-10-31 | 2007-12-12 | Smithkline Beecham Corp | Compounds |
| GB0722077D0 (en) * | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| GB0722075D0 (en) | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| WO2009070533A1 (en) | 2007-11-29 | 2009-06-04 | Complegen, Inc. | Methods of inhibiting steroyl coa desaturase |
| WO2009074487A1 (en) | 2007-12-11 | 2009-06-18 | F. Hoffmann-La Roche Ag | Inhibitors of stearoyl-coa desaturase |
| CA2707313A1 (en) * | 2007-12-11 | 2009-06-18 | Merck Frosst Canada Ltd. | Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| ES2387714T3 (es) | 2007-12-28 | 2012-09-28 | Wisconsin Alumni Research Foundation | Análogos de 2-metilen-20-metil-19,24,25,26,27-pentanor-vitamina D |
| CA2715947C (en) | 2008-02-20 | 2016-10-25 | Novartis Ag | Heterocyclic inhibitors of stearoyl-coa desaturase |
| CA2716109C (en) | 2008-02-28 | 2016-07-19 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
| WO2009117676A2 (en) | 2008-03-20 | 2009-09-24 | Forest Laboratories Holdings Limited | Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase |
| AU2009225513C1 (en) | 2008-03-20 | 2012-01-12 | Forest Laboratories Holdings Limited | Novel piperazine derivatives as inhibitors of stearoyl-CoA desaturase |
| NZ616097A (en) | 2008-03-31 | 2015-04-24 | Vertex Pharma | Pyridyl derivatives as cftr modulators |
| CA2719362A1 (en) | 2008-04-04 | 2009-10-08 | Gilead Sciences, Inc. | Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors |
| JP2011516498A (ja) | 2008-04-04 | 2011-05-26 | ギリアード サイエンシーズ, インコーポレイテッド | ステアロイル−CoAデサチュラーゼの阻害剤として使用するためのトリアゾロピリジノン誘導体 |
| CA2719376A1 (en) | 2008-04-07 | 2009-10-15 | Gilead Sciences, Inc. | 2h-benzo[b][1,4]oxazin-3(4h)-one derivatives for use as stearoyl coa desaturase inhibitors |
| AU2009240747A1 (en) | 2008-04-22 | 2009-10-29 | Merck Frosst Canada Ltd | Novel substituted heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
| GB0810913D0 (en) | 2008-06-13 | 2008-07-23 | Smithkline Beecham Corp | Comppounds |
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
| WO2009156484A2 (en) | 2008-06-27 | 2009-12-30 | Novartis Ag | Organic compounds |
| TWI434842B (zh) | 2008-07-14 | 2014-04-21 | Astellas Pharma Inc | Azole compounds |
| FR2933979B1 (fr) | 2008-07-15 | 2012-08-24 | Pf Medicament | Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine |
| WO2010007482A2 (en) | 2008-07-16 | 2010-01-21 | Glenmark Pharmaceuticals S.A. | Thiazole derivatives as stearoyl coa desaturase inhibitors |
| GB0813740D0 (en) | 2008-07-28 | 2008-09-03 | Angeletti P Ist Richerche Biologica | Therapeutic compounds |
| JP2010043052A (ja) | 2008-08-18 | 2010-02-25 | Mitsubishi Chemicals Corp | カロテノイド類の分離方法 |
| WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| EP2334666A1 (en) | 2008-09-08 | 2011-06-22 | Merck Canada Inc. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2010028761A1 (de) | 2008-09-09 | 2010-03-18 | Sanofi-Aventis | 2-heteroaryl-pyrrolo[3, 4-c]pyrrol-derivate und ihre verwendung als scd inhibitoren |
| WO2010039186A2 (en) | 2008-09-23 | 2010-04-08 | Renovis, Inc. | Compounds useful as faah modulators and uses thereof |
| US20110184027A1 (en) | 2008-09-25 | 2011-07-28 | Glenmark Pharmaceuticals S.A. | Tissue selective stearoyl-coa desaturase 1 inhibitors and cell based screening assay for their identification |
| JP2012504557A (ja) | 2008-10-02 | 2012-02-23 | メルク カナダ インコーポレイテッド | ステアロイルコエンザイムaデルタ−9デサチュラーゼの阻害剤としての芳香族複素環化合物 |
| WO2010045374A1 (en) | 2008-10-15 | 2010-04-22 | Gilead Palo Alto, Inc. | 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors |
| WO2010045371A1 (en) | 2008-10-15 | 2010-04-22 | Gilead Palo Alto, Inc. | Pyrido- and pyrimido (1, 2-a) pyrimidine compounds useful as stearoyl coa desaturase inhibitors |
| CA2740389A1 (en) | 2008-10-15 | 2010-05-20 | Gilead Sciences, Inc. | 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors |
| US20110183958A1 (en) | 2008-10-17 | 2011-07-28 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| GB0821307D0 (en) | 2008-11-21 | 2008-12-31 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| EP2192196A1 (en) | 2008-11-27 | 2010-06-02 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Prediction of lipid-metabotype-related physiological susceptibilities |
| US20100160323A1 (en) | 2008-12-23 | 2010-06-24 | Alexander Bischoff | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE |
| WO2010094120A1 (en) | 2009-02-17 | 2010-08-26 | Merck Frosst Canada Ltd. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| CA2750635A1 (en) | 2009-02-23 | 2010-08-26 | Merck Canada Inc. | Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| ES2761295T3 (es) | 2009-03-02 | 2020-05-19 | Stemsynergy Therapeutics Inc | Métodos y composiciones para su uso en el tratamiento del cáncer y para reducir los efectos mediados por Wnt en una célula |
| JP5642661B2 (ja) | 2009-03-05 | 2014-12-17 | 塩野義製薬株式会社 | Npyy5受容体拮抗作用を有するピペリジンおよびピロリジン誘導体 |
| US20120010186A1 (en) | 2009-03-23 | 2012-01-12 | Merck Frosst Canada Ltd. | Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2010112520A1 (en) | 2009-04-01 | 2010-10-07 | Novartis Ag | Spiro derivatives for the modulation of stearoyl-coa desaturase |
| CA2768577A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| US8383643B2 (en) | 2009-07-28 | 2013-02-26 | Merck Canada Inc. | Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
| FR2948939B1 (fr) | 2009-08-05 | 2013-03-22 | Pf Medicament | Derives de 2h pyridazin-3-ones, leur preparation et leur application en therapeutique humaine |
| US8354403B2 (en) | 2009-08-27 | 2013-01-15 | Merck Sharp & Dohme Corp. | Pyrrolidine derived beta 3 adrenergic receptor agonists |
| DK2473045T3 (en) | 2009-09-01 | 2016-12-12 | Catabasis Pharmaceuticals Inc | Niacin-FATTY ACID CONJUGATES AND THEIR USES |
| EP2475367A1 (en) | 2009-09-10 | 2012-07-18 | Centre National De La Recherche Scientifique | NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES |
| AU2010302577A1 (en) | 2009-10-01 | 2012-03-15 | Novartis Ag | Pyrazole derivatives which modulate stearoyl-CoA desaturase |
| WO2011047481A1 (en) | 2009-10-23 | 2011-04-28 | Merck Frosst Canada Ltd. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2011079274A1 (en) | 2009-12-23 | 2011-06-30 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
| CA2791738C (en) | 2010-03-01 | 2020-06-09 | Gtx, Inc. | Aryl imidazolyl compounds for the treatment of cancer |
| US8796254B2 (en) | 2010-03-31 | 2014-08-05 | Rigel Pharmaceuticals, Inc. | Methods for using carboxamide, sulfonamide and amine compounds |
| FR2958935B1 (fr) | 2010-04-19 | 2012-06-22 | Pf Medicament | Derives d'heterocycles azotes, leur preparation et leur application en therapeutique humaine |
| JP2013532149A (ja) | 2010-06-17 | 2013-08-15 | ノバルティス アーゲー | ピペリジニル置換1,3−ジヒドロ−ベンゾイミダゾール−2−イリデンアミン誘導体 |
| US20130259830A1 (en) | 2010-07-12 | 2013-10-03 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
| HUE052110T2 (hu) | 2010-07-29 | 2021-04-28 | Rigel Pharmaceuticals Inc | AMPK-t aktiváló heterociklusos vegyületek és alkalmazásuk |
| DK2616465T3 (da) | 2010-09-13 | 2016-02-01 | Novartis Ag | Triazin-oxadiazoler |
| JPWO2012046681A1 (ja) | 2010-10-04 | 2014-02-24 | 興和株式会社 | 脂質代謝関連mRNAの発現抑制剤 |
| GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
| AR083904A1 (es) | 2010-11-18 | 2013-04-10 | Prosidion Ltd | Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos |
| EP2455080A1 (en) | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
| EP2455081A1 (en) | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of crohn's disease |
| GB201021103D0 (en) | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | New compounds for the treatment of neurodegenerative diseases |
| EP2651405A2 (en) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| EP2651930B1 (en) | 2010-12-16 | 2015-10-28 | Boehringer Ingelheim International GmbH | Biarylamide inhibitors of leukotriene production |
| KR20120079015A (ko) | 2011-01-03 | 2012-07-11 | 한미약품 주식회사 | G 단백질-커플링된 수용체의 조절을 위한 신규한 비사이클릭 화합물 |
| WO2012123449A1 (en) | 2011-03-14 | 2012-09-20 | Boehringer Ingelheim International Gmbh | N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators |
| JP2014513071A (ja) | 2011-04-04 | 2014-05-29 | シエナ ビオテク ソシエタ ペル アチオニ | ウィント経路遮断薬 |
| CA2833507A1 (en) | 2011-06-07 | 2012-12-13 | Dainippon Sumitomo Pharma Co., Ltd. | Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof |
| WO2012170931A2 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2013004642A1 (en) | 2011-07-01 | 2013-01-10 | Remynd Nv | 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases |
| CN103930424A (zh) | 2011-09-01 | 2014-07-16 | Irm责任有限公司 | 作为c-Kit激酶抑制剂的化合物和组合物 |
| MX342326B (es) | 2011-09-27 | 2016-09-26 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. |
| US9358250B2 (en) | 2011-10-15 | 2016-06-07 | Genentech, Inc. | Methods of using SCD1 antagonists |
| WO2013070660A1 (en) | 2011-11-07 | 2013-05-16 | Emory University | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction |
| WO2013085954A1 (en) | 2011-12-06 | 2013-06-13 | Janssen Pharmaceutica Nv | Substituted piperidinyl-carboxamide derivatives useful as scd 1 inhibitors |
| WO2013085957A1 (en) | 2011-12-06 | 2013-06-13 | Janssen Pharmaceutica Nv | Substituted piperidinyl-pyridazinyl derivatives useful as scd 1 inhibitors |
| US8530461B2 (en) | 2011-12-29 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Azetidine derivatives |
| WO2013130625A1 (en) | 2012-02-27 | 2013-09-06 | Basil Rigas | Phospho-ester derivatives and uses thereof |
| WO2013134546A1 (en) | 2012-03-07 | 2013-09-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| IN2014MN02269A (cg-RX-API-DMAC7.html) | 2012-04-23 | 2015-07-24 | Piramal Entpr Ltd | |
| WO2013170072A2 (en) | 2012-05-09 | 2013-11-14 | Neurop, Inc. | Compounds for the treatment of neurological disorders |
| MX2014014174A (es) | 2012-05-22 | 2015-07-06 | Hoffmann La Roche | Inhibidores selectivos de celulas no diferenciadas. |
| WO2014003153A1 (ja) | 2012-06-28 | 2014-01-03 | 協和発酵キリン株式会社 | 置換アミド化合物 |
| WO2014031928A2 (en) | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
| BR112015007516A2 (pt) | 2012-10-10 | 2017-07-04 | Actelion Pharmaceuticals Ltd | antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona |
| WO2014065860A1 (en) | 2012-10-24 | 2014-05-01 | The General Hospital Corporation | Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions |
| MX2015006930A (es) | 2012-12-03 | 2015-09-08 | Hoffmann La Roche | Compuestos de isoxazol amina sustituidos como inhibidores de scd1. |
| KR20150090100A (ko) | 2012-12-03 | 2015-08-05 | 에프. 호프만-라 로슈 아게 | 스테아로일-CoA 불포화화효소 1(에스씨디 1)의 억제제로서의 치환된 이속사졸 아마이드 화합물 |
| JP2016028016A (ja) | 2012-12-12 | 2016-02-25 | 大日本住友製薬株式会社 | オキサジアゾール誘導体とその医薬用途 |
| US9416102B2 (en) | 2013-01-23 | 2016-08-16 | Wisconsin Alumni Research Foundation | (22E)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3 analogs |
| TWI594975B (zh) | 2013-04-24 | 2017-08-11 | 第一三共股份有限公司 | 二羧酸化合物 |
| KR101524650B1 (ko) | 2013-07-30 | 2015-06-03 | 경상대학교산학협력단 | 테트라하이드로이소퀴놀린 알칼로이드계 화합물 ys-51s를 포함하는 대사성 질환의 예방 및 치료용 조성물 |
| KR20150015305A (ko) | 2013-07-31 | 2015-02-10 | 안동대학교 산학협력단 | 주박 추출물을 유효성분으로 함유하는 비만의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 |
| US20150087673A1 (en) | 2013-09-26 | 2015-03-26 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| WO2015054658A1 (en) | 2013-10-11 | 2015-04-16 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
| CN104163794A (zh) | 2013-10-17 | 2014-11-26 | 中国药科大学 | 2-氨基芳环类血管内皮生长因子受体(vegfr)抑制剂及其制备方法和用途 |
| RU2670762C2 (ru) | 2013-12-31 | 2018-10-25 | Хуаньчжу Фарма Ко., Лтд. | Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака |
| WO2015113920A1 (en) | 2014-01-29 | 2015-08-06 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
| GB201403969D0 (en) | 2014-03-06 | 2014-04-23 | Isis Innovation | Compounds for use in controlling body fat |
| US20170015654A1 (en) | 2014-03-12 | 2017-01-19 | Takeda Pharmaceutical Company Limited | Pyridazine compound |
| US10562869B2 (en) | 2014-03-17 | 2020-02-18 | Remynd Nv | Oxadiazole compounds |
| WO2016022626A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| WO2016022955A1 (en) | 2014-08-07 | 2016-02-11 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
| KR101715449B1 (ko) | 2014-08-13 | 2017-03-30 | 주식회사 큐리언트 | 염증성 질환 치료용 화합물 |
| EP3191578B1 (en) | 2014-09-12 | 2020-11-04 | Whitehead Institute for Biomedical Research | Cells expressing apolipoprotein e and uses thereof |
| WO2016049586A2 (en) | 2014-09-25 | 2016-03-31 | University Of Notre Dame Du Lac | Non-beta lactam antibiotics |
| EP3034500A1 (en) | 2014-12-17 | 2016-06-22 | Genkyotex Sa | Amido thiazole derivatives as NADPH oxidase inhibitors |
| CN105753814A (zh) | 2015-01-01 | 2016-07-13 | 成都贝斯凯瑞生物科技有限公司 | 取代氮杂环衍生物及其应用 |
| US20160223559A1 (en) | 2015-02-02 | 2016-08-04 | The Regents Of The University Of California | Tetrazine-containing compounds and synthetic methods thereof |
| CN107249583B (zh) | 2015-02-09 | 2021-05-07 | 国立大学法人冈山大学 | 乳酸脱氢酶抑制剂以及含有该抑制剂的抗癫痫剂 |
| CN106146391A (zh) | 2015-04-15 | 2016-11-23 | 中国科学院上海药物研究所 | 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途 |
| WO2017066705A1 (en) | 2015-10-14 | 2017-04-20 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
| US20200262799A1 (en) | 2015-11-30 | 2020-08-20 | Universite De Bourgogne | Process for preparing functionalized 1,2,4,5-tetrazine compounds |
| WO2017112777A1 (en) | 2015-12-22 | 2017-06-29 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| RU2018145734A (ru) | 2016-06-08 | 2020-07-14 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Химические соединения в качестве ингибиторов atf4 пути |
| EP3490561A4 (en) | 2016-08-01 | 2020-04-08 | Ignyta, Inc. | COMBINATIONS FOR TREATING CANCER |
| EP3529245A4 (en) | 2016-10-24 | 2020-12-23 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THE LATEST |
| WO2018112077A1 (en) | 2016-12-13 | 2018-06-21 | Centaurus Therapeutics | Inhibitors of dihydroceramide desaturase for treating disease |
| MA47212A (fr) | 2017-01-06 | 2019-11-13 | Yumanity Therapeutics Inc | Méthodes de traitement de troubles neurologiques |
| WO2018160717A1 (en) | 2017-02-28 | 2018-09-07 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
| WO2018161033A1 (en) | 2017-03-02 | 2018-09-07 | Wright, Adrian | Small molecule ire1-alpha inhibitors |
| EP3381908A1 (en) | 2017-03-27 | 2018-10-03 | Leadiant Biosciences SA | 2-(4-(4-(bromo-methoxybenzamido)benzylamino)phenyl)benzazole derivatives and their use as anti-heparanase |
| WO2018195450A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| WO2019018795A1 (en) | 2017-07-20 | 2019-01-24 | Yumanity Therapeutics | COMPOUNDS AND USES THEREOF |
| WO2019084157A1 (en) * | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES THEREOF |
| EP3728201A1 (en) | 2017-12-21 | 2020-10-28 | Gliapharm SA | Compositions and methods of treatment for neurological disorders comprising a dementia |
| US20200325148A1 (en) | 2017-12-21 | 2020-10-15 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising motor neuron diseases |
| EP3737361A4 (en) | 2018-01-11 | 2021-08-25 | Centaurus Therapeutics | INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR THE TREATMENT OF DISEASES |
| ES3053087T3 (en) | 2018-03-05 | 2026-01-19 | Wylder Nation Found | A fatty acid amide hydrolase (faahi) inhibitor for use in inhibiting the cellular accumulation of a sphingolipid in a subject that has lysosomal storage disease or disorder |
| ES3043183T3 (en) | 2018-03-23 | 2025-11-25 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| US11243207B2 (en) | 2018-03-29 | 2022-02-08 | Mayo Foundation For Medical Education And Research | Assessing and treating cancer |
| CN112566636A (zh) | 2018-04-25 | 2021-03-26 | 优曼尼蒂治疗公司 | 化合物及其用途 |
| WO2019209948A1 (en) | 2018-04-25 | 2019-10-31 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| JP2021532181A (ja) | 2018-07-24 | 2021-11-25 | エピザイム,インク. | Smarca2アンタゴニストとして有用なピリジン−2−オン化合物 |
| WO2020132378A2 (en) | 2018-12-22 | 2020-06-25 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising depression |
| MA54829A (fr) | 2019-01-24 | 2021-12-01 | Yumanity Therapeutics Inc | Composés et leurs utilisations |
| US20230078764A1 (en) | 2019-03-22 | 2023-03-16 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| EP4054570A1 (en) | 2019-11-05 | 2022-09-14 | Dermira, Inc | Mrgprx2 antagonists and uses thereof |
| US20230029266A1 (en) | 2019-11-05 | 2023-01-26 | Dermira, Inc. | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| TW202136238A (zh) | 2020-01-06 | 2021-10-01 | 大陸商廣東東陽光藥業有限公司 | RORγt抑制劑及其製備方法和用途 |
| EP4096562B1 (en) | 2020-01-31 | 2025-03-05 | American Sterilizer Company | Surgical light head with beam spreading and adjustable power balancing |
-
2018
- 2018-01-05 MA MA047212A patent/MA47212A/fr unknown
- 2018-01-05 ES ES18735798T patent/ES3025460T3/es active Active
- 2018-01-05 EA EA201991650A patent/EA201991650A1/ru unknown
- 2018-01-05 KR KR1020197022664A patent/KR20190108118A/ko not_active Ceased
- 2018-01-05 WO PCT/US2018/012697 patent/WO2018129403A1/en not_active Ceased
- 2018-01-05 BR BR112019013954-0A patent/BR112019013954A2/pt unknown
- 2018-01-05 CA CA3049010A patent/CA3049010A1/en active Pending
- 2018-01-05 US US15/863,773 patent/US10973810B2/en active Active
- 2018-01-05 CN CN201880016244.5A patent/CN110392833A/zh active Pending
- 2018-01-05 JP JP2019536521A patent/JP2020514293A/ja active Pending
- 2018-01-05 MX MX2019008124A patent/MX2019008124A/es unknown
- 2018-01-05 IL IL304017A patent/IL304017A/en unknown
- 2018-01-05 EP EP18735798.3A patent/EP3566055B1/en active Active
- 2018-01-05 AU AU2018205275A patent/AU2018205275B2/en not_active Ceased
-
2019
- 2019-07-03 IL IL267818A patent/IL267818A/en unknown
-
2021
- 2021-04-09 US US17/226,233 patent/US12433880B2/en active Active
-
2022
- 2022-12-19 JP JP2022201688A patent/JP2023036752A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA47212A (fr) | 2019-11-13 |
| IL267818A (en) | 2019-09-26 |
| AU2018205275A1 (en) | 2019-07-25 |
| WO2018129403A1 (en) | 2018-07-12 |
| JP2020514293A (ja) | 2020-05-21 |
| US10973810B2 (en) | 2021-04-13 |
| ES3025460T3 (en) | 2025-06-09 |
| US20180193325A1 (en) | 2018-07-12 |
| EP3566055B1 (en) | 2025-03-12 |
| BR112019013954A2 (pt) | 2020-02-11 |
| CN110392833A (zh) | 2019-10-29 |
| MX2019008124A (es) | 2019-12-05 |
| JP2023036752A (ja) | 2023-03-14 |
| CA3049010A1 (en) | 2018-07-12 |
| EP3566055A4 (en) | 2020-12-02 |
| AU2018205275B2 (en) | 2024-05-02 |
| IL304017A (en) | 2023-08-01 |
| US12433880B2 (en) | 2025-10-07 |
| EP3566055A1 (en) | 2019-11-13 |
| US20220040167A1 (en) | 2022-02-10 |
| EA201991650A1 (ru) | 2020-01-20 |
| EP3566055C0 (en) | 2025-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12433880B2 (en) | Methods for the treatment of neurological disorders | |
| AU2013251632B2 (en) | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | |
| EP2805718B1 (en) | Heterocyclic amide derivative and pharmaceutical product containing same | |
| JP2019112449A (ja) | 嚢胞性線維症を処置するための新規化合物およびこれらの医薬組成物 | |
| JP5292100B2 (ja) | Gk活性化作用を有する2−ピリジンカルボキサミド誘導体 | |
| EP4157834B1 (en) | N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction | |
| US11472784B2 (en) | Griseofulvin compound | |
| JP2022546717A (ja) | Usp30阻害剤としての活性を有する置換シアノピロリジン類 | |
| US20130324556A1 (en) | Protease Activated Receptor 2 (PAR2) Antagonists | |
| CN115698001A (zh) | 具有作为usp30抑制剂活性的n-氰基吡咯烷类化合物 | |
| US20180125801A1 (en) | Methods for selecting phosphatase selective and non-selective phosphatase inhibitors | |
| US20250034122A1 (en) | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors | |
| CN105646492B (zh) | 含五元芳杂环的取代黄嘌呤类化合物及其制备方法和用途 | |
| US7449462B2 (en) | Triazole derivatives which inhibit vasopressin antagonistic activity | |
| US20200222400A1 (en) | Methods for the treatment of neurological disorders | |
| CN118302422A (zh) | 具有作为usp30抑制剂的活性的取代的n-氰基吡咯烷 | |
| HK40068349B (en) | Substituted cyanopyrrolidines with activity as usp30 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20190801 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20201230 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230217 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230801 Patent event code: PE09021S01D |
|
| E90F | Notification of reason for final refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20240201 Patent event code: PE09021S02D |
|
| PE0601 | Decision on rejection of patent |
Patent event date: 20240701 Comment text: Decision to Refuse Application Patent event code: PE06012S01D |